{"content":"<li class=\"n-box-item date-title\" data-end=\"1545281999\" data-start=\"1545195600\" data-txt=\"Monday, December 23, 2019\">Wednesday, December 19, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3418392\" data-ts=\"1545275717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NWL\" target=\"_blank\">NWL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418392-newell-brandsplus-5-icahn-increases-active-stake-to-9_9\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Newell Brands +5% as Icahn increases active stake to 9.9%</a></h4><ul><li>Newell Brands (NASDAQ:<a href='https://seekingalpha.com/symbol/NWL' title='Newell Brands Inc.'>NWL</a>) <font color=\"green\">+5.1%</font> after-hours as activist investor Carl Icahn discloses he has <a href=\"https://www.marketwatch.com/story/newell-brands-stock-gains-after-icahn-increases-stake-2018-12-19\" target=\"_blank\">raised his stake</a> in the company to 9.9% from a previous holding of 8.3%.</li><li>An <a href=\"https://www.sec.gov/Archives/edgar/data/814453/000092846418000166/nwlsch13damd4121918.htm\" target=\"_blank\">SEC filing</a> shows Icahn and his son Brett bought more than 1M shares last month at $20-$20.50 each.</li><li>In April, NWL agreed to add four new board members recommended by Carl Icahn, including Brett Icahn.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418392\" data-linked=\"Newell Brands +5% as Icahn increases active stake to 9.9%\" data-tweet=\"$NWL - Newell Brands +5% as Icahn increases active stake to 9.9% https://seekingalpha.com/news/3418392-newell-brandsplus-5-icahn-increases-active-stake-to-9_9?source=tweet\" data-url=\"https://seekingalpha.com/news/3418392-newell-brandsplus-5-icahn-increases-active-stake-to-9_9\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>40&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418390\" data-ts=\"1545275299\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CE\" target=\"_blank\">CE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418390-celanese-to-join-s-and-p-500-sharesplus-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celanese to join S&amp;P 500; shares +4%</a></h4><ul><li>Celanese (NYSE:<a href='https://seekingalpha.com/symbol/CE' title='Celanese Corporation'>CE</a>) <font color=\"green\">+4.4%</font> after-hours on news it will <a href=\"https://seekingalpha.com/pr/17363537-celanese-set-join-s-and-p-500\" target=\"_blank\">join the S&amp;P 500</a> effective prior to the open of trading on Dec. 24.</li><li>CE will replace Express Scripts, which will be acquired by Cigna in a deal expected to close soon.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418390\" data-linked=\"Celanese to join S&amp;P 500; shares +4%\" data-tweet=\"$CE - Celanese to join S&amp;P 500; shares +4% https://seekingalpha.com/news/3418390-celanese-to-join-s-and-p-500-sharesplus-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3418390-celanese-to-join-s-and-p-500-sharesplus-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418380\" data-ts=\"1545258809\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SURF\" target=\"_blank\">SURF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418380-sppi-penn-mlhr-among-notable-after-hour-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SPPI, PENN &amp; MLHR among notable after hour movers</a></h4><ul><li><strong>Gainers: </strong><a href='https://seekingalpha.com/symbol/SURF' title='Surface Oncology'>SURF</a> <font color=\"green\">+18.7%</font>. <a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a> <font color=\"green\">+9.7%</font>. <a href='https://seekingalpha.com/symbol/MLHR' title='Herman Miller, Inc.'>MLHR</a> <font color=\"green\">+8.9%</font>. <a href='https://seekingalpha.com/symbol/PENN' title='Penn National Gaming, Inc.'>PENN</a> <font color=\"green\">+6.3%</font>. <a href='https://seekingalpha.com/symbol/GNBC' title='Green Bancorp'>GNBC</a> <font color=\"green\">+5.7%</font>.</li><li><strong>Losers: </strong><a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a> <font color=\"red\">-35.9%</font>. <a href='https://seekingalpha.com/symbol/GTHX' title='G1 Therapeutics'>GTHX</a> <font color=\"red\">-23.9%</font>. <a href='https://seekingalpha.com/symbol/REVG' title='REV Group'>REVG</a> <font color=\"red\">-11.1%</font>. <a href='https://seekingalpha.com/symbol/LMNR' title='Limoneira'>LMNR</a> <font color=\"red\">-5.0%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418380\" data-linked=\"SPPI, PENN &amp; MLHR among notable after hour movers\" data-tweet=\"$SURF $SURF $TLRY - SPPI, PENN &amp; MLHR among notable after hour movers https://seekingalpha.com/news/3418380-sppi-penn-mlhr-among-notable-after-hour-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3418380-sppi-penn-mlhr-among-notable-after-hour-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:33 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418365\" data-ts=\"1545256708\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NBEV\" target=\"_blank\">NBEV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418365-new-age-beverages-up-3-after-hours-on-tilray-ab-inbev-collaboration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Age Beverages up 3% after hours on Tilray/AB InBev collaboration</a></h4><ul><li>New Age Beverages (NASDAQ:<a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a>) is up <font color=\"green\">3%</font> after hours on average volume apparently stoked by Tilray's collaboration with AB InBev aimed at non-alcoholic drinks containing THC and CBD.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418346-tilray-teams-ab-inbev-non-alcoholic-beverages-thc-cbd-shares-10-percent-hours\" target=\"_blank\">Tilray teams up with AB InBev in non-alcoholic beverages with THC and CBD; shares up 10% after hours</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418365\" data-linked=\"New Age Beverages up 3% after hours on Tilray/AB InBev collaboration\" data-tweet=\"$NBEV - New Age Beverages up 3% after hours on Tilray/AB InBev collaboration https://seekingalpha.com/news/3418365-new-age-beverages-up-3-after-hours-on-tilray-ab-inbev-collaboration?source=tweet\" data-url=\"https://seekingalpha.com/news/3418365-new-age-beverages-up-3-after-hours-on-tilray-ab-inbev-collaboration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418359\" data-ts=\"1545256404\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GTHX\" target=\"_blank\">GTHX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418359-g1-therapeutics-trilaciclib-fails-to-beat-placebo-in-mid-stage-lung-cancer-study-shares-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">G1 Therapeutics&#39; trilaciclib fails to beat placebo in mid-stage lung cancer study; shares down 24% after hours</a></h4><ul><li>G1 Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/GTHX' title='G1 Therapeutics'>GTHX</a>) slumps <font color=\"red\">24%</font> after hours on the heels of its <a href=\"https://seekingalpha.com/pr/17363341-g1-therapeutics-announces-positive-topline-results-randomized-phase-2-trial-trilaciclib\" target=\"_blank\">announcement </a>of topline data from a <a href=\"https://clinicaltrials.gov/ct2/show/NCT02514447?lead=g1+therapeutics&amp;phase=1&amp;rank=5\" target=\"_blank\">Phase 2 clinical trial</a> evaluating trilaciclib, combined with chemo agent topotecan, for the second- and third-line treatment of small cell lung cancer &#40;SCLC&#41;.</li><li>The objective response rate &#40;ORR&#41; was 13.3% (n=4/30), well below 23.1% (n=6/26) for placebo. The disease control rates (responders + stable cancer) were similar, 60.0% for the treatment group and 61.5% for control, as was median progression-free survival &#40;PFS&#41;, both 4.2 months. Overall survival had not been reached at data cutoff.</li><li>The company plans to meet with U.S. and European regulatory authorities to discuss the totality of data and pathways to approval.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418359\" data-linked=\"G1 Therapeutics&#39; trilaciclib fails to beat placebo in mid-stage lung cancer study; shares down 24% after hours\" data-tweet=\"$GTHX - G1 Therapeutics&#39; trilaciclib fails to beat placebo in mid-stage lung cancer study; shares down 24% after hours https://seekingalpha.com/news/3418359-g1-therapeutics-trilaciclib-fails-to-beat-placebo-in-mid-stage-lung-cancer-study-shares-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3418359-g1-therapeutics-trilaciclib-fails-to-beat-placebo-in-mid-stage-lung-cancer-study-shares-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:53 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418348\" data-ts=\"1545255647\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAD\" target=\"_blank\">RAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418348-rite-aidplus-8_5-after-fy2019-guidance-mckesson-pact\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rite Aid +8.5% after FY2019 guidance, McKesson pact</a></h4><ul><li>Rite Aid (NYSE:<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>) <font color=\"green\">jumps 8.5%</font> in after-hours trading<a href=\"https://seekingalpha.com/pr/17363399-rite-aid-reports-fiscal-2019-third-quarter-results\" target=\"_blank\"> FY2019 guidance</a> shows revenue will meet or beat consensus estimate and that the drugstore chain has amended a drug purchasing pact with McKesson (NYSE:<a href='https://seekingalpha.com/symbol/MCK' title='McKesson Corporation'>MCK</a>).</li><li><strong>FY2019 guidance:</strong> total revenue of $21.8B-$21.95B vs consensus estimate of $21.8B.</li><li>Adjusted net loss per share of 1 cent-3 cents vs. consensus of break-even.</li><li>Same-store sales increase of 0.5%-1.0%.</li><li>Separately, Rite Aid announces <a href=\"https://seekingalpha.com/pr/17363392-rite-aid-mckesson-agree-key-terms-pharmaceutical-purchasing-distribution\" target=\"_blank\">an amendment</a> to its drug purchasing agreement with McKesson, \"continuing our relationship for an additional 10 years and providing us with competitive drug pricing and operating flexibility that will help drive future growth,\u201d says Rite Aid CEO John Standley</li><li>Also, a substantially completed refinancing of its revolving credit facility will extend its debt maturities and provide additional liquidity.</li><li><a href=\"https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.riteaid.com&amp;esheet=51916925&amp;newsitemid=20181219005812&amp;lan=en-US&amp;anchor=www.riteaid.com&amp;index=1&amp;md5=2a0e79781871ef1c850c40e676270664\" target=\"_blank\">Conference call </a>at 5:00 PM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418333-rite-aid-beats-0_01-revenue-line\" target=\"_blank\">Rite Aid beats by $0.01, revenue in-line</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418348\" data-linked=\"Rite Aid +8.5% after FY2019 guidance, McKesson pact\" data-tweet=\"$RAD $RAD $MCK - Rite Aid +8.5% after FY2019 guidance, McKesson pact https://seekingalpha.com/news/3418348-rite-aidplus-8_5-after-fy2019-guidance-mckesson-pact?source=tweet\" data-url=\"https://seekingalpha.com/news/3418348-rite-aidplus-8_5-after-fy2019-guidance-mckesson-pact\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418346\" data-ts=\"1545255395\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TLRY\" target=\"_blank\">TLRY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418346-tilray-teams-up-ab-inbev-in-non-alcoholic-beverages-thc-and-cbd-shares-up-10-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tilray teams up with AB InBev in non-alcoholic beverages with THC and CBD; shares up 10% after hours</a></h4><ul><li>Cannabis producer Tilray (NASDAQ:<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>) will <a href=\"https://seekingalpha.com/pr/17363446-ab-inbev-tilray-announce-research-partnership-focused-non-alcohol-thc-cbd-beverages\" target=\"_blank\">partner </a>with AB InBev to research non-alcoholic beverages containing tetrahydrocannabinol &#40;THC&#41; and cannabidiol &#40;CBD&#41;. The potential commercialization of the drinks will be confined to Canada.</li><li>Each company plans to invest up to $50M in the effort. Further details are undisclosed.</li><li>TLRY is up <font color=\"green\">10%</font> after hours.</li><li>Peers Cronos Group (NASDAQ:<a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a>) and Canopy Growth (NYSE:<a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>) are both up <font color=\"green\">1%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418346\" data-linked=\"Tilray teams up with AB InBev in non-alcoholic beverages with THC and CBD; shares up 10% after hours\" data-tweet=\"$TLRY $TLRY $CRON - Tilray teams up with AB InBev in non-alcoholic beverages with THC and CBD; shares up 10% after hours https://seekingalpha.com/news/3418346-tilray-teams-up-ab-inbev-in-non-alcoholic-beverages-thc-and-cbd-shares-up-10-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3418346-tilray-teams-up-ab-inbev-in-non-alcoholic-beverages-thc-and-cbd-shares-up-10-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>55&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418335\" data-ts=\"1545254407\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SPPI\" target=\"_blank\">SPPI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418335-fda-declines-accelerated-review-status-for-spectrums-poziotinib-for-certain-lung-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA declines accelerated review status for Spectrum&#39;s poziotinib for certain lung cancer patients; shares down 31% after hours</a></h4><ul><li>Spectrum Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/SPPI' title='Spectrum Pharmaceuticals, Inc.'>SPPI</a>) slumps <font color=\"red\">31%</font> after hours on the heels of its <a href=\"https://seekingalpha.com/pr/17363335-spectrum-pharmaceuticals-provides-poziotinib-update\" target=\"_blank\">announcement </a>that the FDA has declined to designate poziotinib a Breakthrough Therapy for EGFR exon 20-positive non-small cell lung cancer &#40;NSCLC&#41;.</li><li>Despite the setback for accelerated review, the company says its development plan and timeline remain unchanged. A <a href=\"https://clinicaltrials.gov/ct2/show/NCT03318939?intr=Poziotinib&amp;lead=spectrum+pharmaceuticals&amp;rank=3\" target=\"_blank\">Phase 2</a> study in these patients is in process with an estimated primary completion date of June 2022.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418335\" data-linked=\"FDA declines accelerated review status for Spectrum&#39;s poziotinib for certain lung cancer patients; shares down 31% after hours\" data-tweet=\"$SPPI - FDA declines accelerated review status for Spectrum&#39;s poziotinib for certain lung cancer patients; shares down 31% after hours https://seekingalpha.com/news/3418335-fda-declines-accelerated-review-status-for-spectrums-poziotinib-for-certain-lung-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3418335-fda-declines-accelerated-review-status-for-spectrums-poziotinib-for-certain-lung-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:20 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418333\" data-ts=\"1545254217\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAD\" target=\"_blank\">RAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418333-rite-aid-beats-0_01-revenue-in-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rite Aid beats by $0.01,  revenue in-line</a></h4><ul><li>Rite Aid (NYSE:<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>): Q3 Non-GAAP EPS of $0.01 <span style=\"color:green\">beats by $0.01</span>; GAAP EPS of -$0.02 <span style=\"color:green\">beats by $0.02</span>.</li><li>Revenue of $5.45B (+1.9% Y/Y) in-line.</li><li>Shares <font color=\"green\">+6%</font>.</li><li><a href=\"https://seekingalpha.com/pr/17363399-rite-aid-reports-fiscal-2019-third-quarter-results\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418333\" data-linked=\"Rite Aid beats by $0.01,  revenue in-line\" data-tweet=\"$RAD - Rite Aid beats by $0.01, revenue in-line https://seekingalpha.com/news/3418333-rite-aid-beats-0_01-revenue-in-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3418333-rite-aid-beats-0_01-revenue-in-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:16 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>76&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418329\" data-ts=\"1545254023\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FOLD\" target=\"_blank\">FOLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418329-new-finance-chief-amicus-therapeutics-shares-up-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New finance chief at Amicus Therapeutics; shares up 4% after hours</a></h4><ul><li>Amicus Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/FOLD' title='Amicus Therapeutics, Inc.'>FOLD</a>) <a href=\"https://seekingalpha.com/pr/17363339-amicus-therapeutics-announces-executive-team-updates\" target=\"_blank\">promotes </a>SVP, Finance and Administration Daphne Quimi to Chief Financial Officer succeeding Chip Baird who will depart next quarter. She has been with the company for 11 years.</li><li>Shares are up <font color=\"green\">4%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418329\" data-linked=\"New finance chief at Amicus Therapeutics; shares up 4% after hours\" data-tweet=\"$FOLD - New finance chief at Amicus Therapeutics; shares up 4% after hours https://seekingalpha.com/news/3418329-new-finance-chief-amicus-therapeutics-shares-up-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3418329-new-finance-chief-amicus-therapeutics-shares-up-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:13 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418322\" data-ts=\"1545253610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MNKD\" target=\"_blank\">MNKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418322-mannkind-launches-equity-offering-shares-down-14-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MannKind launches equity offering; shares down 14% after hours</a></h4><ul><li>MannKind (NASDAQ:<a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a>) <a href=\"https://seekingalpha.com/pr/17363345-mannkind-announces-commencement-public-offering\" target=\"_blank\">commences </a>a public offering of stock and warrants. Prices, volume and terms have yet to be announced. Shares are off <font color=\"red\">14%</font> after hours.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418322\" data-linked=\"MannKind launches equity offering; shares down 14% after hours\" data-tweet=\"$MNKD - MannKind launches equity offering; shares down 14% after hours https://seekingalpha.com/news/3418322-mannkind-launches-equity-offering-shares-down-14-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3418322-mannkind-launches-equity-offering-shares-down-14-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>21&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418309\" data-ts=\"1545251231\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADI\" target=\"_blank\">ADI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418309-analyst-downgrades-adi-on-near-term-risks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analyst downgrades ADI on near-term risks</a></h4><ul><li>Morgan Stanley <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+Morgan+Stanley+Downgrades+Analog+Devices+%28ADI%29+to+Equalweight/14936532.html\" target=\"_blank\">downgrades </a>Analog Devices (NASDAQ:<a href='https://seekingalpha.com/symbol/ADI' title='Analog Devices Inc.'>ADI</a>) from Overweight to Equal-Weight with a $100 price target.</li><li>Analyst Craig Hettenbach says ADI's guidance is well ahead of its peers but those elevated estimates will make it harder for near-term outperformance considering the ongoing semi risks in 2019.</li><li>ADI shares are <font color=\"red\">down 4.5%</font> to $84.13.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418309\" data-linked=\"Analyst downgrades ADI on near-term risks\" data-tweet=\"$ADI - Analyst downgrades ADI on near-term risks https://seekingalpha.com/news/3418309-analyst-downgrades-adi-on-near-term-risks?source=tweet\" data-url=\"https://seekingalpha.com/news/3418309-analyst-downgrades-adi-on-near-term-risks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:27 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418307\" data-ts=\"1545250909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418307-rough-session-for-high-yield-after-fed-hike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rough session for high-yield after Fed hike</a></h4><ul><li>Long-term Treasury rates <a href=\"https://seekingalpha.com/news/3418288-ten-year-yield-slides-surprise-fed-hawkishness\" target=\"_blank\">are falling sharply</a> after the Fed hiked by 25 basis points and signaled the cycle is not yet done.</li><li>High-yield, however, is headed the other way, with the iShares High Yield Corporate Bond ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/HYG' title='iShares iBoxx $ High Yield Corporate Bond ETF'>HYG</a>) and the SPDR High Yield Bond ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/JNK' title='SPDR Bloomberg Barclays High Yield Bond ETF'>JNK</a>) both in the red.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418305-game-chicken-fed-stocks\" target=\"_blank\">Game of chicken between Fed and stocks</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418307\" data-linked=\"Rough session for high-yield after Fed hike\" data-tweet=\"$HYG $JNK - Rough session for high-yield after Fed hike https://seekingalpha.com/news/3418307-rough-session-for-high-yield-after-fed-hike?source=tweet\" data-url=\"https://seekingalpha.com/news/3418307-rough-session-for-high-yield-after-fed-hike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418306\" data-ts=\"1545250880\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MTCH\" target=\"_blank\">MTCH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418306-match-group-fires-comm-vp-involved-in-suit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Match Group fires comm VP involved in suit</a></h4><ul><li>Match Group (NASDAQ:<a href='https://seekingalpha.com/symbol/MTCH' title='Match Group, Inc.'>MTCH</a>) <font color=\"red\">drops 1.6%</font> after yesterday's <a href=\"https://www.theverge.com/2018/12/18/18146668/tinder-lawsuit-match-rosette-pambakian-fired\" target=\"_blank\">The Verge</a> report that the company fired VP of marketing and communications Rosette Pambakian after she participated in a $2B suit against the company.</li><li>Multiple Tinder employees involved in the lawsuit were fired. In the original suit, Pambakian claimed former Tinder CEO Greg Blatt sexually assaulted her.</li><li>The Verge obtained an email between Pambakian, Match Group CEO Mandy Ginsberg, and Tinder CEO Elie Seidman where Pambakian said she was subjected to \u201congoing intimidation and retaliation\u201d to get her to resign. Pambakian also said she was fired a day before her options vested.</li><li>Read the full email exchange at The Verge.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418306\" data-linked=\"Match Group fires comm VP involved in suit\" data-tweet=\"$MTCH - Match Group fires comm VP involved in suit https://seekingalpha.com/news/3418306-match-group-fires-comm-vp-involved-in-suit?source=tweet\" data-url=\"https://seekingalpha.com/news/3418306-match-group-fires-comm-vp-involved-in-suit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:21 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418305\" data-ts=\"1545250128\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418305-game-of-chicken-fed-and-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Game of chicken between Fed and stocks</a></h4><ul><li><a href=\"https://twitter.com/MilwaukeeBonds/status/1075469706457419777\" target=\"_blank\">Portfolio manager Will Slaughter</a>: \"I\u2019d say this decision is a disaster ... Markets will throw a tantrum to force Powell to comply.\"</li><li>Equity markets have been screaming \"uncle,\" but the Fed isn't hearing it, hiking rates today and signaling more moves next year (though down to two from three). That's still way more than the roughly zero rate hikes short-term interest rate markets have been pricing in.</li><li>Stock investors are thus hitting the \"sell\" button post-Fed, sending the Nasdaq <font color=\"red\">down 2.5%</font> and S&amp;P 500 <font color=\"red\">2.0%</font> as Chairman Jay Powell gives his press conference (<a href=\"https://seekingalpha.com/news/3418296-cross-currents-emerged-feds-powell\" target=\"_blank\">live coverage here</a>).</li><li>The yield curve is flattening further, with the 10-year yield all the way down to 2.75% vs. the new Fed Funds rate at 2.25-2.5%. The two-year yield is at 2.64%. The 30-year yield is now below 3% for the first time in four months.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/DIA' title='SPDR Dow Jones Industrial Average ETF'>DIA</a>, <a href='https://seekingalpha.com/symbol/CRF' title='Cornerstone Total Return Fund'>CRF</a>, <a href='https://seekingalpha.com/symbol/USA' title='Liberty All-Star Equity Fund'>USA</a>, <a href='https://seekingalpha.com/symbol/UDOW' title='ProShares UltraPro Dow 30 ETF'>UDOW</a>, <a href='https://seekingalpha.com/symbol/DOG' title='ProShares Short Dow 30 ETF'>DOG</a>, <a href='https://seekingalpha.com/symbol/DXD' title='ProShares UltraShort Dow30 ETF'>DXD</a>, <a href='https://seekingalpha.com/symbol/SDOW' title='ProShares UltraPro Short Dow 30 ETF'>SDOW</a>, <a href='https://seekingalpha.com/symbol/SCHX' title='Schwab U.S. Large-Cap ETF'>SCHX</a>, <a href='https://seekingalpha.com/symbol/ZF' title='Virtus Total Return Fund Inc'>ZF</a>, <a href='https://seekingalpha.com/symbol/DDM' title='ProShares Ultra Dow 30 ETF'>DDM</a>, <a href='https://seekingalpha.com/symbol/VV' title='Vanguard Large Cap ETF'>VV</a>, <a href='https://seekingalpha.com/symbol/FEX' title='First Trust Large Cap Core AlphaDEX ETF'>FEX</a>, <a href='https://seekingalpha.com/symbol/JKD' title='iShares Morningstar Large-Cap ETF'>JKD</a>, <a href='https://seekingalpha.com/symbol/EQL' title='ALPS Equal Sector Weight ETF'>EQL</a>, <a href='https://seekingalpha.com/symbol/EEH' title='ELEMENTS SPECTRUM Large Cap U.S. Sector ETN'>EEH</a>, <a href='https://seekingalpha.com/symbol/IWL' title='iShares Russell Top 200 ETF'>IWL</a>, <a href='https://seekingalpha.com/symbol/FWDD' title='AdvisorShares Madrona Domestic ETF'>FWDD</a>, <a href='https://seekingalpha.com/symbol/EDOW' title='First Trust Dow 30 Equal Weight ETF'>EDOW</a>, <a href='https://seekingalpha.com/symbol/SYE' title='SPDR MFS Systematic Core Equity ETF'>SYE</a>, <a href='https://seekingalpha.com/symbol/JHML' title='John Hancock Multifactor Large Cap ETF'>JHML</a>, <a href='https://seekingalpha.com/symbol/UDPIX' title='ProFunds Ultra Dow 30 ProFund Inv'>UDPIX</a>, <a href='https://seekingalpha.com/symbol/GSEW' title='Goldman Sachs Equal Weight U.S. Large Cap Equity ETF'>GSEW</a>, <a href='https://seekingalpha.com/symbol/ESGL' title='Oppenheimer ESG Revenue ETF'>ESGL</a>, <a href='https://seekingalpha.com/symbol/HUSV' title='First Trust Horizon Managed Volatility Domestic ETF'>HUSV</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418305\" data-linked=\"Game of chicken between Fed and stocks\" data-tweet=\"$DIA $CRF $USA - Game of chicken between Fed and stocks https://seekingalpha.com/news/3418305-game-of-chicken-fed-and-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3418305-game-of-chicken-fed-and-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>185&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418303\" data-ts=\"1545249684\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRIN\" target=\"_blank\">MRIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418303-microcaps-mostly-among-tech-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps mostly among tech movers</a></h4><ul><li><strong>Gainers: </strong>Marin Software (NASDAQ:<a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software'>MRIN</a>) <font color=\"green\">+92%</font>. Sonic Foundry (<a href='https://seekingalpha.com/symbol/SOFO' title='Sonic Foundry, Inc.'>OTC:SOFO</a>) <font color=\"green\">+23%</font>. Internap (NASDAQ:<a href='https://seekingalpha.com/symbol/INAP' title='Internap Network Services Corporation'>INAP</a>) <font color=\"green\">+19%</font>. GigaMedia (NASDAQ:<a href='https://seekingalpha.com/symbol/GIGM' title='GigaMedia Limited'>GIGM</a>) <font color=\"green\">+11%</font>. Castlight Health (NYSE:<a href='https://seekingalpha.com/symbol/CSLT' title='Castlight Health, Inc.'>CSLT</a>) <font color=\"green\">+9%</font>.</li> <li><strong>Losers: </strong>Gridsum Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/GSUM' title='Gridsum Holding'>GSUM</a>) <font color=\"red\">-12%</font>. Veritone (NASDAQ:<a href='https://seekingalpha.com/symbol/VERI' title='Veritone'>VERI</a>) <font color=\"red\">-10%</font>. Atomera Incorporated (NASDAQ:<a href='https://seekingalpha.com/symbol/ATOM' title='Atomera Inc.'>ATOM</a>) <font color=\"red\">-9%</font>. Cincinnati Bell (NYSE:<a href='https://seekingalpha.com/symbol/CBB' title='Cincinnati Bell Inc.'>CBB</a>) <font color=\"red\">-8%</font>. Veeco Instruments (NASDAQ:<a href='https://seekingalpha.com/symbol/VECO' title='Veeco Instruments Inc.'>VECO</a>) <font color=\"red\">-8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3418303\" data-linked=\"Microcaps mostly among tech movers\" data-tweet=\"$MRIN $MRIN $SOFO - Microcaps mostly among tech movers https://seekingalpha.com/news/3418303-microcaps-mostly-among-tech-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3418303-microcaps-mostly-among-tech-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418297\" data-ts=\"1545248381\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVDA\" target=\"_blank\">NVDA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418297-semi-stocks-slide-after-fed-hike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Semi stocks slide after Fed hike</a></h4><ul><li>Semi stocks slide after the Fed rate hike with the Philadelphia Semiconductor index <font color=\"red\">down 1%</font>. Top movers include (<a href='https://seekingalpha.com/symbol/NVDA' title='NVIDIA Corporation'>NVDA</a> <font color='red'>-2.7%</font>), (<a href='https://seekingalpha.com/symbol/NXPI' title='NXP Semiconductors'>NXPI</a> <font color='red'>-3.3%</font>), (<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a> <font color='red'>-2.1%</font>), and (<a href='https://seekingalpha.com/symbol/ON' title='ON Semiconductor Corporation'>ON</a> <font color='red'>-3.3%</font>).</li><li>The overall sector (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>) is<font color=\"green\"> up 0.6%</font> with the S&amp;P 500 IT index <font color=\"green\">up 0.2%</font> and the Nasdaq 100 <font color=\"green\">up 0.3%</font>.</li><li>Related broad tech ETFs: <a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>, <a href='https://seekingalpha.com/symbol/VGT' title='Vanguard Information Technology ETF'>VGT</a>, <a href='https://seekingalpha.com/symbol/TECL' title='Direxion Technology Bull 3x Shares ETF'>TECL</a>, <a href='https://seekingalpha.com/symbol/FTEC' title='Fidelity MSCI Information Technology Index ETF'>FTEC</a>, <a href='https://seekingalpha.com/symbol/IYW' title='iShares U.S. Technology ETF'>IYW</a>, <a href='https://seekingalpha.com/symbol/ROM' title='ProShares Ultra Technology ETF'>ROM</a>, <a href='https://seekingalpha.com/symbol/QTEC' title='First Trust NASDAQ-100-Tech Index ETF'>QTEC</a>, <a href='https://seekingalpha.com/symbol/RYT' title='Invesco S&P 500 Equal Weight Technology ETF'>RYT</a>, <a href='https://seekingalpha.com/symbol/FNG' title='AdvisorShares New Tech and Media ETF'>FNG</a>, <a href='https://seekingalpha.com/symbol/TECS' title='Direxion Technology Bear 3x Shares ETF'>TECS</a>, <a href='https://seekingalpha.com/symbol/IGM' title='iShares North American Tech ETF'>IGM</a>, <a href='https://seekingalpha.com/symbol/FXL' title='First Trust Tech AlphaDEX ETF'>FXL</a>, <a href='https://seekingalpha.com/symbol/XNTK' title='SPDR NYSE Technology ETF'>XNTK</a>, <a href='https://seekingalpha.com/symbol/REW' title='ProShares UltraShort Technology ETF'>REW</a>, <a href='https://seekingalpha.com/symbol/JHMT' title='John Hancock Multifactor Technology ETF'>JHMT</a>, <a href='https://seekingalpha.com/symbol/XITK' title='SPDR Innovative Technology ETF'>XITK</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418286-federal-reserve-raises-interest-rates-neutral-rate-estimate-moves-lower\" target=\"_blank\">The Federal Reserve raises interest rates - neutral rate estimate moves lower</a> (Dec. 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418290-fed-trims-growth-inflation-rate-outlooks\" target=\"_blank\">Fed trims growth, inflation, rate outlooks</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418297\" data-linked=\"Semi stocks slide after Fed hike\" data-tweet=\"$NVDA $NVDA $NXPI - Semi stocks slide after Fed hike https://seekingalpha.com/news/3418297-semi-stocks-slide-after-fed-hike?source=tweet\" data-url=\"https://seekingalpha.com/news/3418297-semi-stocks-slide-after-fed-hike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>57&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418293\" data-ts=\"1545247911\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418293-emerging-markets-give-up-gains-after-fed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Emerging markets give up gains after Fed</a></h4><ul><li><font color=\"green\">Up more than 1%</font> prior to the FOMC announcement, the iShares MSCI Emerging Markets ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/EEM' title='iShares MSCI Emerging Markets ETF'>EEM</a>) is now about flat on the session.</li><li>The Fed hiked 25 basis points and indicated the need for continued rate increases in 2019 - disappointing many who had expected the language to hint that a pause in the cycle was at hand.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418285-fed-mostly-sticks-guns-stocks-head-lower\" target=\"_blank\">Fed mostly sticks to its guns, stocks head lower</a> (Dec. 19)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/EEM' title='iShares MSCI Emerging Markets ETF'>EEM</a>, <a href='https://seekingalpha.com/symbol/VWO' title='Vanguard FTSE Emerging Markets ETF'>VWO</a>, <a href='https://seekingalpha.com/symbol/IEMG' title='iShares Core MSCI Emerging Markets ETF'>IEMG</a>, <a href='https://seekingalpha.com/symbol/EDC' title='Direxion Daily Emerging Markets Bull 3x Shares ETF'>EDC</a>, <a href='https://seekingalpha.com/symbol/SCHE' title='Schwab Emerging Markets ETF'>SCHE</a>, <a href='https://seekingalpha.com/symbol/EDZ' title='Direxion Daily Emerging Markets Bear 3x Shares ETF'>EDZ</a>, <a href='https://seekingalpha.com/symbol/EMF' title='Templeton Emerging Markets Fund'>EMF</a>, <a href='https://seekingalpha.com/symbol/MSF' title='Morgan Stanley Emerging Markets Fund'>MSF</a>, <a href='https://seekingalpha.com/symbol/ADRE' title='Invesco BLDRS Emerging Markets 50 ADR Index ETF'>ADRE</a>, <a href='https://seekingalpha.com/symbol/EEV' title='ProShares UltraShort MSCI Emerging Markets ETF'>EEV</a>, <a href='https://seekingalpha.com/symbol/EUM' title='ProShares Short MSCI Emerging Markets ETF'>EUM</a>, <a href='https://seekingalpha.com/symbol/EET' title='ProShares Ultra MSCI Emerging Markets ETF'>EET</a>, <a href='https://seekingalpha.com/symbol/SPEM' title='SPDR Portfolio Emerging Markets ETF'>SPEM</a>, <a href='https://seekingalpha.com/symbol/EEME' title='iShares MSCI Emerging Markets EMEA Index ETF'>EEME</a>, <a href='https://seekingalpha.com/symbol/XSOE' title='WisdomTree Emerging Markets ex-State-Owned Enterprises Fund'>XSOE</a>, <a href='https://seekingalpha.com/symbol/DBEM' title='Deutsche X-trackers MSCI Emerging Markets Hedged Equity ETF'>DBEM</a>, <a href='https://seekingalpha.com/symbol/FEM' title='First Trust Emerging Markets AlphaDEX ETF'>FEM</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418293\" data-linked=\"Emerging markets give up gains after Fed\" data-tweet=\"$EEM $VWO $IEMG - Emerging markets give up gains after Fed https://seekingalpha.com/news/3418293-emerging-markets-give-up-gains-after-fed?source=tweet\" data-url=\"https://seekingalpha.com/news/3418293-emerging-markets-give-up-gains-after-fed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418288\" data-ts=\"1545247186\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418288-ten-year-yield-slides-after-surprise-fed-hawkishness\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ten-year yield slides after surprise Fed hawkishness</a></h4><ul><li>The Fed minutes ago surprised most, hiking rates another 25 basis points, and indicating it continues to see the need for further tightening of policy.</li><li>Stocks have given up big early gains and the 10-year Treasury yield has whooshed four basis points lower to 2.79%. <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a> <font color=\"green\">+1.1%</font>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a> <font color=\"red\">-2.2%</font></li><li>It's not all hawkishness though - the Fed now expects just two rate hikes in 2019 vs. three previously.</li><li>A check of the dollar (UUP]], <a href='https://seekingalpha.com/symbol/UDN' title='Invesco DB US Dollar Index Bearish ETF'>UDN</a>) finds it higher post-Fed but still in the red for the day. Gold (NYSEARCA:<a href='https://seekingalpha.com/symbol/GLD' title='SPDR Gold Trust ETF'>GLD</a>) has given up its gains, now <font color=\"red\">down 0.35%</font> on the session.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418285-fed-mostly-sticks-guns-stocks-head-lower\" target=\"_blank\">Fed mostly sticks to its guns, stocks head lower</a> (Dec. 19)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/TLT' title='iShares 20+ Year Treasury Bond ETF'>TLT</a>, <a href='https://seekingalpha.com/symbol/TBT' title='ProShares UltraShort 20+ Year Treasury ETF'>TBT</a>, <a href='https://seekingalpha.com/symbol/TMV' title='Direxion Daily 20+ Year Treasury Bear 3x Shares ETF'>TMV</a>, <a href='https://seekingalpha.com/symbol/TBF' title='ProShares Short 20+ Year Treasury ETF'>TBF</a>, <a href='https://seekingalpha.com/symbol/EDV' title='Vanguard Extended Duration Treasury ETF'>EDV</a>, <a href='https://seekingalpha.com/symbol/TMF' title='Direxion Daily 30-Year Treasury Bull 3x Shares ETF'>TMF</a>, <a href='https://seekingalpha.com/symbol/TTT' title='ProShares UltraPro Short 20+ Year Treasury ETF'>TTT</a>, <a href='https://seekingalpha.com/symbol/ZROZ' title='PIMCO 25+ Year Zero Coupon U.S. Treasury Index ETF'>ZROZ</a>, <a href='https://seekingalpha.com/symbol/VGLT' title='Vanguard Long-Term Treasury ETF'>VGLT</a>, <a href='https://seekingalpha.com/symbol/TLH' title='iShares 10-20 Year Treasury Bond ETF'>TLH</a>, <a href='https://seekingalpha.com/symbol/UBT' title='ProShares Ultra 20+ Year Treasury ETF'>UBT</a>, <a href='https://seekingalpha.com/symbol/SPTL' title='SPDR Portfolio Long Term Treasury ETF'>SPTL</a>, <a href='https://seekingalpha.com/symbol/DLBS' title='iPath U.S. Treasury Long Bond Bear ETN'>DLBS</a>, <a href='https://seekingalpha.com/symbol/VUSTX' title='Vanguard Long Term Treasury Fund Inv'>VUSTX</a>, <a href='https://seekingalpha.com/symbol/TYBS' title='Direxion Daily 20+ Year Treasury Bear 1x Shares ETF'>TYBS</a>, <a href='https://seekingalpha.com/symbol/DLBL-OLD' title='iPath U.S. Treasury Long Bond Bull ETN'>DLBL-OLD</a>, <a href='https://seekingalpha.com/symbol/OPER' title='ClearShares Ultra-Short Maturity ETF'>OPER</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418288\" data-linked=\"Ten-year yield slides after surprise Fed hawkishness\" data-tweet=\"$TLT $TBT $UUP - Ten-year yield slides after surprise Fed hawkishness https://seekingalpha.com/news/3418288-ten-year-yield-slides-after-surprise-fed-hawkishness?source=tweet\" data-url=\"https://seekingalpha.com/news/3418288-ten-year-yield-slides-after-surprise-fed-hawkishness\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:19 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>94&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418281\" data-ts=\"1545246043\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGE\" target=\"_blank\">TGE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418281-tallgrass-energy-and-ramaco-resources-among-energy-materials-gainers-fts-international-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tallgrass Energy and Ramaco Resources among Energy/Materials gainers; FTS International and Key Energy Services among losers</a></h4><ul><li><b>Gainers: </b>Tallgrass Energy (NYSE:<a href='https://seekingalpha.com/symbol/TGE' title='Tallgrass Energy LP Class A'>TGE</a>) <font color=\"green\">+14%</font>. Ramaco Resources (NASDAQ:<a href='https://seekingalpha.com/symbol/METC' title='Ramaco'>METC</a>) <font color=\"green\">+12%</font>. Calumet Specialty Products Partners (NASDAQ:<a href='https://seekingalpha.com/symbol/CLMT' title='Calumet Specialty Products Partners, L.P.'>CLMT</a>) <font color=\"green\">+12%</font>. Marrone Bio Innovations (NASDAQ:<a href='https://seekingalpha.com/symbol/MBII' title='Marrone Bio Innovations, Inc.'>MBII</a>) <font color=\"green\">+11%</font>. Baytex Energy (NYSE:<a href='https://seekingalpha.com/symbol/BTE' title='Baytex Energy Corp.'>BTE</a>) <font color=\"green\">+10%</font>.</li><li><b>Losers: </b>FTS International (NYSE:<a href='https://seekingalpha.com/symbol/FTSI' title='FTS International, Inc.'>FTSI</a>) <font color=\"red\">-13%</font>. Key Energy Services (NYSE:<a href='https://seekingalpha.com/symbol/KEG' title='Key Energy Services, Inc.'>KEG</a>) <font color=\"red\">-9%</font>. PEDEVCO (NYSEMKT:<a href='https://seekingalpha.com/symbol/PED' title='PEDEVCO Corp.'>PED</a>) <font color=\"red\">-9%</font>. Pacific Ethanol (NASDAQ:<a href='https://seekingalpha.com/symbol/PEIX' title='Pacific Ethanol, Inc.'>PEIX</a>) <font color=\"red\">-8%</font>. Golden Star Resources (NYSEMKT:<a href='https://seekingalpha.com/symbol/GSS' title='Golden Star Resource Corp'>GSS</a>) <font color=\"red\">-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418281\" data-linked=\"Tallgrass Energy and Ramaco Resources among Energy/Materials gainers; FTS International and Key Energy Services among losers\" data-tweet=\"$TGE $TGE $METC - Tallgrass Energy and Ramaco Resources among Energy/Materials gainers; FTS International and Key Energy Services among losers https://seekingalpha.com/news/3418281-tallgrass-energy-and-ramaco-resources-among-energy-materials-gainers-fts-international-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3418281-tallgrass-energy-and-ramaco-resources-among-energy-materials-gainers-fts-international-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418276\" data-ts=\"1545245288\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABBV\" target=\"_blank\">ABBV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418276-abbvie-teams-up-voluntis-in-companion-digital-therapeutics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AbbVie teams up with Voluntis in companion digital therapeutics</a></h4><ul><li>AbbVie (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color=\"green\">+2.1%</font>) will <a href=\"https://seekingalpha.com/pr/17363117-abbvie-voluntis-develop-companion-digital-therapeutics\" target=\"_blank\">collaborate </a>with healthcare software developer <a href=\"http://www.voluntis.com/\" target=\"_blank\">Voluntis </a>to develop a solution designed to enhance the coordination of patient care in immunology via digital therapeutic software.</li><li>The French firm will leverage its <a href=\"http://www.voluntis.com/oncology/\" target=\"_blank\">Theraxium </a>technology that helps patients self-manage their symptoms via a smartphone app. It is collaborating with Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a> <font color=\"red\">-1%</font>) in hemophilia and AstraZeneca (<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a> <font color=\"green\">+0.4%</font>) in cancer.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418276\" data-linked=\"AbbVie teams up with Voluntis in companion digital therapeutics\" data-tweet=\"$ABBV $ABBV $RHHBY - AbbVie teams up with Voluntis in companion digital therapeutics https://seekingalpha.com/news/3418276-abbvie-teams-up-voluntis-in-companion-digital-therapeutics?source=tweet\" data-url=\"https://seekingalpha.com/news/3418276-abbvie-teams-up-voluntis-in-companion-digital-therapeutics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418273\" data-ts=\"1545245020\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FTNW\" target=\"_blank\">FTNW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418273-fte-networks-announces-stock-buyback-program\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FTE Networks announces stock buyback program</a></h4><ul><li>FTE Networks (<a href='https://seekingalpha.com/symbol/FTNW' title='FTE Networks, Inc.'>FTNW</a> <font color='green'>+9.2%</font>) board has <a href=\"https://seekingalpha.com/pr/17362681-fte-networks-announces-4-million-corporate-stock-buyback-program\" target=\"_blank\">approved</a> a stock repurchase program of up to $4M of the Company\u2019s outstanding common stock, beginning Dec. 19, 2018.</li><li>The stock buyback program is effective for a three-year period.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418273\" data-linked=\"FTE Networks announces stock buyback program\" data-tweet=\"$FTNW - FTE Networks announces stock buyback program https://seekingalpha.com/news/3418273-fte-networks-announces-stock-buyback-program?source=tweet\" data-url=\"https://seekingalpha.com/news/3418273-fte-networks-announces-stock-buyback-program\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:43 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418258\" data-ts=\"1545242450\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MHLD\" target=\"_blank\">MHLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418258-maiden-holdings-leads-financial-gainers-medley-management-and-noah-holdings-among-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Maiden Holdings leads financial gainers; Medley Management and Noah Holdings among losers</a></h4><ul><li><b>Gainers:</b> Maiden Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MHLD' title='Maiden Hldgs Ltd'>MHLD</a>) <font color=\"green\">+9%</font>. Kingstone Companies (NASDAQ:<a href='https://seekingalpha.com/symbol/KINS' title='Kingstone Companies Inc'>KINS</a>) <font color=\"green\">+7%</font>. American International Group (NYSE:<a href='https://seekingalpha.com/symbol/AIG' title='American International Group Inc'>AIG</a>) <font color=\"green\">+6%</font>. LM Funding America (NASDAQ:<a href='https://seekingalpha.com/symbol/LMFA' title='LM Funding America, Inc.'>LMFA</a>) <font color=\"green\">+6%</font>. Government Properties Income Trust (NYSE:<a href='https://seekingalpha.com/symbol/GOV-OLD' title='Government Properties Income Trust'>GOV-OLD</a>) <font color=\"green\">+6%</font>.</li><li><b>Losers:</b> China Rapid Finance (NYSE:<a href='https://seekingalpha.com/symbol/XRF' title='China Rapid Finance'>XRF</a>) <font color=\"red\">-18%</font>. CBL &amp; Associates Properties (NYSE:<a href='https://seekingalpha.com/symbol/CBL' title='CBL & Associates Properties, Inc.'>CBL</a>) <font color=\"red\">-6%</font>. Medley Management (NYSE:<a href='https://seekingalpha.com/symbol/MDLY' title='Medley Management'>MDLY</a>) <font color=\"red\">-5%</font>. Noah Holdings (NYSE:<a href='https://seekingalpha.com/symbol/NOAH' title='Noah Holdings Limited'>NOAH</a>) <font color=\"red\">-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418258\" data-linked=\"Maiden Holdings leads financial gainers; Medley Management and Noah Holdings among losers\" data-tweet=\"$MHLD $MHLD $KINS - Maiden Holdings leads financial gainers; Medley Management and Noah Holdings among losers https://seekingalpha.com/news/3418258-maiden-holdings-leads-financial-gainers-medley-management-and-noah-holdings-among-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3418258-maiden-holdings-leads-financial-gainers-medley-management-and-noah-holdings-among-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418254\" data-ts=\"1545241329\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRIN\" target=\"_blank\">MRIN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418254-microcaps-mostly-among-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps mostly among midday movers</a></h4><ul><li><strong>Gainers: </strong>Marin Software (NASDAQ:<a href='https://seekingalpha.com/symbol/MRIN' title='Marin Software'>MRIN</a>) <font color=\"green\">+55%</font>. Adial Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADIL' title='ADial Pharmaceuticals, Inc'>ADIL</a>) <font color=\"green\">+22%</font>. Internap (NASDAQ:<a href='https://seekingalpha.com/symbol/INAP' title='Internap Network Services Corporation'>INAP</a>) <font color=\"green\">+19%</font>. ABM Industries Incorporated (NYSE:<a href='https://seekingalpha.com/symbol/ABM' title='ABM Industries Incorporated'>ABM</a>) <font color=\"green\">+18%</font>. AutoWeb (NASDAQ:<a href='https://seekingalpha.com/symbol/AUTO' title='AutoWeb, Inc.'>AUTO</a>) <font color=\"green\">+18%</font>. Limbach Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LMB' title='Limbach Holdings, Inc'>LMB</a>) <font color=\"green\">+17%</font>. Winnebago Industries (NYSE:<a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a>) <font color=\"green\">+17%</font>. China Automotive Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a>) <font color=\"green\">+16%</font>. Cellect Biotechnology (NASDAQ:<a href='https://seekingalpha.com/symbol/APOP' title='Cellect Biotechnology Ltd.'>APOP</a>) <font color=\"green\">+14%</font>. Motus GI Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MOTS' title='Motus GI Holdings'>MOTS</a>) <font color=\"green\">+14%</font>.</li> <li><strong>Losers: </strong>Surface Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/SURF' title='Surface Oncology'>SURF</a>) <font color=\"red\">-33%</font>. Biocept (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a>) <font color=\"red\">-27%</font>. China Rapid Finance (NYSE:<a href='https://seekingalpha.com/symbol/XRF' title='China Rapid Finance'>XRF</a>) <font color=\"red\">-16%</font>. PLx Pharma (NASDAQ:<a href='https://seekingalpha.com/symbol/PLXP' title='PLx Pharma'>PLXP</a>) <font color=\"red\">-14%</font>. Gridsum Holding (NASDAQ:<a href='https://seekingalpha.com/symbol/GSUM' title='Gridsum Holding'>GSUM</a>) <font color=\"red\">-14%</font>. ASLAN Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ASLN' title='ASLAN Pharmaceuticals'>ASLN</a>) <font color=\"red\">-14%</font>. Fortress Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/FBIO' title='Fortress Biotech, Inc.'>FBIO</a>) <font color=\"red\">-13%</font>. FTS International (NYSE:<a href='https://seekingalpha.com/symbol/FTSI' title='FTS International, Inc.'>FTSI</a>) <font color=\"red\">-13%</font>. Forty Seven (NASDAQ:<a href='https://seekingalpha.com/symbol/FTSV' title='Forty Seven'>FTSV</a>) <font color=\"red\">-13%</font>. Allakos (NASDAQ:<a href='https://seekingalpha.com/symbol/ALLK' title='Allakos'>ALLK</a>) <font color=\"red\">-12%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3418254\" data-linked=\"Microcaps mostly among midday movers\" data-tweet=\"$MRIN $MRIN $ADIL - Microcaps mostly among midday movers https://seekingalpha.com/news/3418254-microcaps-mostly-among-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3418254-microcaps-mostly-among-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418252\" data-ts=\"1545241222\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418252-d-c-ag-files-suit-against-facebook-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">D.C. AG files suit against Facebook (update)</a></h4><ul><li>The attorney general for the District of Columbia filed suit against Facebook (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a>) for allowing Cambridge Analytica to access personal data without permission, according to <a href=\"https://www.washingtonpost.com/technology/2018/12/19/dc-attorney-general-sues-facebook-over-alleged-privacy-violations-cambridge-analytica-scandal/?utm_term=.aae44c7dd29d\" target=\"_blank\">The Washington Post</a> sources.</li><li>A source says the suit is likely to be amended in the future with other, more recent allegations of improper data use.</li><li>Facebook shares are<font color=\"red\"> down 4%</font> to $137.72.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418090-another-personal-data-scandal-facebook-update\" target=\"_blank\">Another personal data scandal for Facebook (update)</a> (Dec. 19)</li><li><strong>Update:</strong> AG Karl Racine confirms the suit with a <a href=\"https://oag.dc.gov/release/ag-racine-sues-facebook-failing-protect-millions\" target=\"_blank\">press release.</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418252\" data-linked=\"D.C. AG files suit against Facebook (update)\" data-tweet=\"$FB - D.C. AG files suit against Facebook (update) https://seekingalpha.com/news/3418252-d-c-ag-files-suit-against-facebook-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3418252-d-c-ag-files-suit-against-facebook-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>179&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418251\" data-ts=\"1545240736\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BNFT\" target=\"_blank\">BNFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418251-analysts-positive-on-benefitfocus-after-event-bnftplus-5_5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts positive on Benefitfocus after event; BNFT +5.5%</a></h4><ul><li>Benefitfocus (NASDAQ:<a href='https://seekingalpha.com/symbol/BNFT' title='Benefitfocus, Inc.'>BNFT</a>) <font color=\"green\">gains 5.5%</font> on positive analyst comments following the company's investor event.</li><li>Wedbush analyst Daniel Ives has increased confidence in the company's \"ability to hit its strong 2019 guidance.\" Rating is Outperform with a $57 price target.</li><li>Raymond James analyst Brian Peterson thinks investors should take comfort in the 2019 forecast looking \"achievable (if not conservative).\" Rating at Outperform with a $58 target.</li><li>Source: Bloomberg First Word.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418251\" data-linked=\"Analysts positive on Benefitfocus after event; BNFT +5.5%\" data-tweet=\"$BNFT - Analysts positive on Benefitfocus after event; BNFT +5.5% https://seekingalpha.com/news/3418251-analysts-positive-on-benefitfocus-after-event-bnftplus-5_5?source=tweet\" data-url=\"https://seekingalpha.com/news/3418251-analysts-positive-on-benefitfocus-after-event-bnftplus-5_5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:32 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418247\" data-ts=\"1545239443\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CI\" target=\"_blank\">CI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418247-new-jersey-on-board-cigna-express-scripts-tie-up\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Jersey on board with Cigna/Express Scripts tie-up</a></h4><ul><li>Cigna (<a href='https://seekingalpha.com/symbol/CI' title='Cigna Corporation'>CI</a> <font color=\"green\">+2.8%</font>) <a href=\"https://www.sec.gov/Archives/edgar/data/701221/000095015918000531/cigna8k.htm\" target=\"_blank\">reports </a>that the state of New Jersey has signed off on its planned merger with Express Scripts (<a href='https://seekingalpha.com/symbol/ESRX' title='Express Scripts, Inc.'>ESRX</a> <font color=\"green\">+1.9%</font>).</li><li>The transaction should close tomorrow.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418247\" data-linked=\"New Jersey on board with Cigna/Express Scripts tie-up\" data-tweet=\"$CI $CI $ESRX - New Jersey on board with Cigna/Express Scripts tie-up https://seekingalpha.com/news/3418247-new-jersey-on-board-cigna-express-scripts-tie-up?source=tweet\" data-url=\"https://seekingalpha.com/news/3418247-new-jersey-on-board-cigna-express-scripts-tie-up\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418244\" data-ts=\"1545239186\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OREXQ\" target=\"_blank\">OREXQ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418244-orexigen-up-32-on-expanded-contrave-distribution-in-asia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Orexigen up 32% on expanded Contrave distribution in Asia</a></h4><ul><li>Thinly traded nano cap Orexigen Therapeutics (<a href='https://seekingalpha.com/symbol/OREXQ' title='OREXIGEN THERAPEUTICS INC'>OTCPK:OREXQ</a> <font color=\"green\">+31.6%</font>), a wholly owned subsidiary of Nalpropion Pharmaceuticals, is up, albeit on only 11K shares, on the heels of its <a href=\"https://seekingalpha.com/pr/17363082-nalpropion-pharmaceuticals-inc-expands-agreement-inova-pharmaceuticals-exclusive\" target=\"_blank\">agreement </a>with iNova for exclusive commercialization rights to Contrave (naltrexone HCl/bupropion HCl extended-release) in additional countries in Southeast Asia, Africa and the Pacific, adding market opportunity to its existing territory of Australia, New Zealand and South Africa.</li><li>Under the terms of the deal, Orexigen will receive $23M upon closing and will supply product at an undisclosed transfer price.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418244\" data-linked=\"Orexigen up 32% on expanded Contrave distribution in Asia\" data-tweet=\"$OREXQ - Orexigen up 32% on expanded Contrave distribution in Asia https://seekingalpha.com/news/3418244-orexigen-up-32-on-expanded-contrave-distribution-in-asia?source=tweet\" data-url=\"https://seekingalpha.com/news/3418244-orexigen-up-32-on-expanded-contrave-distribution-in-asia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418245\" data-ts=\"1545238978\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WGO\" target=\"_blank\">WGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418245-general-mills-and-winnebago-industries-among-consumer-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">General Mills and Winnebago Industries among consumer gainers</a></h4><ul><li><b>Gainers: </b>Winnebago Industries (NYSE:<a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a>) <font color=\"green\">+16%</font>. China Automotive Systems (NASDAQ:<a href='https://seekingalpha.com/symbol/CAAS' title='China Automotive Systems, Inc.'>CAAS</a>) <font color=\"green\">+9%</font>. General Mills (NYSE:<a href='https://seekingalpha.com/symbol/GIS' title='General Mills, Inc.'>GIS</a>) <font color=\"green\">+7%</font>. LCI Industries (NYSE:<a href='https://seekingalpha.com/symbol/LCII' title='LCI Industries'>LCII</a>) <font color=\"green\">+6%</font>. Naked Brand Group (NASDAQ:<a href='https://seekingalpha.com/symbol/NAKD' title='Naked Brand Group Limited'>NAKD</a>) <font color=\"green\">+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418245\" data-linked=\"General Mills and Winnebago Industries among consumer gainers\" data-tweet=\"$WGO $WGO $CAAS - General Mills and Winnebago Industries among consumer gainers https://seekingalpha.com/news/3418245-general-mills-and-winnebago-industries-among-consumer-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3418245-general-mills-and-winnebago-industries-among-consumer-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:02 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418243\" data-ts=\"1545238847\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DNOW\" target=\"_blank\">DNOW</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418243-nowminus-2_8-stifel-steps-to-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NOW -2.8% as Stifel steps to sidelines</a></h4><ul><li>Stifel <a href=\"https://www.streetinsider.com/Analyst+Comments/Stifel+Downgrades+Now+Inc+%28DNOW%29+to+Hold/14936575.html\" target=\"_blank\">downgrades</a> NOW (NYSE:<a href='https://seekingalpha.com/symbol/DNOW' title='NOW Inc.'>DNOW</a>) from Buy to Hold and cuts the target by $4 to $13.</li><li>The firm feels positive on management and longer-term potential, but there's too much uncertainty to justify a Buy rating.</li><li>NOW shares are <font color=\"red\">down 2.8%</font> to $11.45.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418243\" data-linked=\"NOW -2.8% as Stifel steps to sidelines\" data-tweet=\"$DNOW - NOW -2.8% as Stifel steps to sidelines https://seekingalpha.com/news/3418243-nowminus-2_8-stifel-steps-to-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3418243-nowminus-2_8-stifel-steps-to-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418242\" data-ts=\"1545238580\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADMA\" target=\"_blank\">ADMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418242-adma-bio-up-9-waiting-for-fda-response-to-bivigam-bla-amendment\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ADMA Bio up 9% waiting for FDA response to Bivigam BLA amendment</a></h4><ul><li>Thinly traded micro cap ADMA Biologics (<a href='https://seekingalpha.com/symbol/ADMA' title='ADMA Biologics Inc'>ADMA</a> <font color=\"green\">+9%</font>) is up on modestly higher volume. Investors are <a href=\"https://seekingalpha.com/pr/17362861-adma-biologics-provides-regulatory-update-bivigam\" target=\"_blank\">expecting good news</a> from the FDA on the company's BLA amendment for BIVIGAM (intravenous immune globulin [human], 10%) which, if approved, will clear the way for a relaunch early next year.</li><li>Production was <a href=\"https://seekingalpha.com/news/3374286-fda-accepts-adma-bios-bivigam-application-amendment-action-date-october-25-shares-18-percent\" target=\"_blank\">shut down</a> to allow time to upgrade and renovate the production facility.</li><li>The agency's action date was October 25, but was <a href=\"https://seekingalpha.com/news/3396674-fda-extends-review-period-admas-bla-amendment-bivigam\" target=\"_blank\">extended</a> until yesterday to allow for the review of additional information submitted by the company at the agency's request.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418242\" data-linked=\"ADMA Bio up 9% waiting for FDA response to Bivigam BLA amendment\" data-tweet=\"$ADMA - ADMA Bio up 9% waiting for FDA response to Bivigam BLA amendment https://seekingalpha.com/news/3418242-adma-bio-up-9-waiting-for-fda-response-to-bivigam-bla-amendment?source=tweet\" data-url=\"https://seekingalpha.com/news/3418242-adma-bio-up-9-waiting-for-fda-response-to-bivigam-bla-amendment\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418234\" data-ts=\"1545237630\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PTE\" target=\"_blank\">PTE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418234-polarityte-up-11-on-skinte-adoption-cleveland-healthcare-network\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PolarityTE up 11% on SkinTE adoption by Cleveland healthcare network</a></h4><ul><li>PolarityTE (<a href='https://seekingalpha.com/symbol/PTE' title='PolarityTE, Inc.'>PTE</a> <font color=\"green\">+10.6%</font>) is up on below-average volume in response to its <a href=\"https://seekingalpha.com/pr/17362544-polarityte-university-hospitals-cleveland-medical-center-announce-system-wide-approval-skinte\" target=\"_blank\">announcement </a>that its SkinTE autologous human cellular and tissue-based product is now available throughout the University Hospital network in northern Ohio that includes 18 hospitals, more than 40 outpatient clinics and 200 physician offices.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3299056-polarityte-go-u-s-commercialization-lead-candidate-skinte\" target=\"_blank\">PolarityTE on go with U.S. commercialization of lead candidate SkinTE</a> (Oct. 3, 2017)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418234\" data-linked=\"PolarityTE up 11% on SkinTE adoption by Cleveland healthcare network\" data-tweet=\"$PTE - PolarityTE up 11% on SkinTE adoption by Cleveland healthcare network https://seekingalpha.com/news/3418234-polarityte-up-11-on-skinte-adoption-cleveland-healthcare-network?source=tweet\" data-url=\"https://seekingalpha.com/news/3418234-polarityte-up-11-on-skinte-adoption-cleveland-healthcare-network\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418232\" data-ts=\"1545236897\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CIVI\" target=\"_blank\">CIVI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418232-civitas-up-12-on-17_75-share-takeover-bid\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Civitas up 12% on $17.75/share takeover bid</a></h4><ul><li>Thinly traded Civitas Solutions (<a href='https://seekingalpha.com/symbol/CIVI' title='Civitas Solutions'>CIVI</a> <font color=\"green\">+12.4%</font>) is up on whopping 97x surge in volume following at $17.75/share <a href=\"https://seekingalpha.com/pr/17362134-civitas-solutions-enters-definitive-merger-agreement-acquired-centerbridge-17_75-per-share\" target=\"_blank\">takeover bid</a> from Centerbridge Partners L.P., valuing the company at ~$1.4B.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418232\" data-linked=\"Civitas up 12% on $17.75/share takeover bid\" data-tweet=\"$CIVI - Civitas up 12% on $17.75/share takeover bid https://seekingalpha.com/news/3418232-civitas-up-12-on-17_75-share-takeover-bid?source=tweet\" data-url=\"https://seekingalpha.com/news/3418232-civitas-up-12-on-17_75-share-takeover-bid\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418229\" data-ts=\"1545236291\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXTA\" target=\"_blank\">AXTA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418229-coating-stocks-on-rise-axalta-guidance-in-line-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Coating stocks on the rise as Axalta guidance in-line with consensus</a></h4><ul><li>Coating stocks gain in late morning trading after Axalta's (<a href='https://seekingalpha.com/symbol/AXTA' title='Axalta Coating Systems'>AXTA</a> <font color='green'>+5%</font>) 2019 guidance, in-line with buyside expectations, came in more positive than some peers, RBC analyst Arun Viswanathan wrote in a note.</li><li>Other paint and coatings makers rising: PPG Industries (<a href='https://seekingalpha.com/symbol/PPG' title='PPG Industries, Inc.'>PPG</a> <font color='green'>+2.4%</font>), Sherwin-Williams (<a href='https://seekingalpha.com/symbol/SHW' title='The Sherwin-Williams Company'>SHW</a> <font color='green'>+1.8%</font>), and RPM International.(<a href='https://seekingalpha.com/symbol/RPM' title='RPM International Inc.'>RPM</a> <font color='green'>+0.9%</font>).</li><li>Source: Bloomberg First Word.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3400831-axalta-coating-systems-beats-0_03-misses-revenue\" target=\"_blank\">Axalta Coating Systems beats by $0.03, misses on revenue</a> (Oct. 25)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418229\" data-linked=\"Coating stocks on the rise as Axalta guidance in-line with consensus\" data-tweet=\"$AXTA $AXTA $PPG - Coating stocks on the rise as Axalta guidance in-line with consensus https://seekingalpha.com/news/3418229-coating-stocks-on-rise-axalta-guidance-in-line-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3418229-coating-stocks-on-rise-axalta-guidance-in-line-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:18 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418224\" data-ts=\"1545235744\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIMT\" target=\"_blank\">AIMT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418224-aimmune-launches-late-stage-study-of-ar101-in-young-children-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aimmune launches late-stage study of AR101 in young children; shares up 3%</a></h4><ul><li>Aimmune Therapeutics (<a href='https://seekingalpha.com/symbol/AIMT' title='Aimmune Therapeutics'>AIMT</a> <font color=\"green\">+2.5%</font>) <a href=\"https://seekingalpha.com/pr/17362523-aimmune-therapeutics-initiates-phase-3-poseidon-trial-treatment-peanut-allergy-1-3-year-old\" target=\"_blank\">initiates </a>a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT03736447?lead=aimmune+therapeutics&amp;phase=2&amp;rank=1\" target=\"_blank\">POSEIDON</a>, evaluating peanut allergy candidate AR101 in peanut-allergic children ages 1-3 years.</li><li>The primary endpoint of the 105-subject study is the proportion of patients who can tolerate at least 600 mg of peanut protein (~two kernels) with no more than mild allergic symptoms during a food challenge. The estimated primary completion date is November 2020.</li><li>An earlier Phase 3, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02635776?lead=aimmune+therapeutics&amp;phase=2&amp;rank=8\" target=\"_blank\">PALISADE</a>, in young people aged 4-17 showed that 85% of those who completed the study tolerated the challenge dose of 500-600 mg of peanut protein.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418224\" data-linked=\"Aimmune launches late-stage study of AR101 in young children; shares up 3%\" data-tweet=\"$AIMT - Aimmune launches late-stage study of AR101 in young children; shares up 3% https://seekingalpha.com/news/3418224-aimmune-launches-late-stage-study-of-ar101-in-young-children-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3418224-aimmune-launches-late-stage-study-of-ar101-in-young-children-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418222\" data-ts=\"1545235538\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SF\" target=\"_blank\">SF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418222-stifel-slumps-after-wells-fargo-cuts-on-pessimistic-2019-outlook\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stifel slumps after Wells Fargo cuts on pessimistic 2019 outlook</a></h4><ul><li>Stifel Financial (<a href='https://seekingalpha.com/symbol/SF' title='Stifel Financial Corporation'>SF</a> <font color=\"red\">-1.4%</font>) sank as much as 3.9% after Wells Fargo cuts its rating to market perform from outperform, saying Q4 \"is likely to represent the peak for profit margins this cycle.\"</li><li>Analysts led by Christopher Harris write that net interest, asset management and investment banking revenue may \"slow substantially during the next year because of weaker equity markets, fewer interest rate increases and a less favorable capital markets backdrop.\"</li><li>Sees double-digit percentage declines for institutional brokerage revenue in 2019 and 2020.</li><li>Price target cut to $44 from $49.</li><li>Source: Bloomberg First Word.</li><li><a href=\"https://seekingalpha.com/symbol/SF/earnings/analyst_ratings\" target=\"_blank\">Analyst ratings</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3409209-stifel-boosts-stock-buyback\" target=\"_blank\">Stifel boosts stock buyback</a> (Nov. 13)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418222\" data-linked=\"Stifel slumps after Wells Fargo cuts on pessimistic 2019 outlook\" data-tweet=\"$SF - Stifel slumps after Wells Fargo cuts on pessimistic 2019 outlook https://seekingalpha.com/news/3418222-stifel-slumps-after-wells-fargo-cuts-on-pessimistic-2019-outlook?source=tweet\" data-url=\"https://seekingalpha.com/news/3418222-stifel-slumps-after-wells-fargo-cuts-on-pessimistic-2019-outlook\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418221\" data-ts=\"1545235441\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADIL\" target=\"_blank\">ADIL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418221-aduro-biotech-and-polarityte-among-healthcare-gainers-biocept-and-fortress-biotech-among\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aduro BioTech and PolarityTE among healthcare gainers; Biocept and Fortress Biotech among losers</a></h4><ul><li><b>Gainers: </b>Adial Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADIL' title='ADial Pharmaceuticals, Inc'>ADIL</a>) <font color=\"green\">+16%</font>. Motus GI Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/MOTS' title='Motus GI Holdings'>MOTS</a>) <font color=\"green\">+13%</font>. Aduro BioTech (NASDAQ:<a href='https://seekingalpha.com/symbol/ADRO' title='Aduro Biotech'>ADRO</a>) <font color=\"green\">+13%</font>. PolarityTE (NASDAQ:<a href='https://seekingalpha.com/symbol/PTE' title='PolarityTE, Inc.'>PTE</a>) <font color=\"green\">+13%</font>. Civitas Solutions (NYSE:<a href='https://seekingalpha.com/symbol/CIVI' title='Civitas Solutions'>CIVI</a>) <font color=\"green\">+12%</font>.</li><li><b>Losers: </b>Surface Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/SURF' title='Surface Oncology'>SURF</a>) <font color=\"red\">-31%</font>. Biocept (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a>) <font color=\"red\">-28%</font>. Fortress Biotech (NASDAQ:<a href='https://seekingalpha.com/symbol/FBIO' title='Fortress Biotech, Inc.'>FBIO</a>) <font color=\"red\">-13%</font>. Sophiris Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/SPHS' title='Sophiris Bio'>SPHS</a>) <font color=\"red\">-10%</font>. Provention Bio (NASDAQ:<a href='https://seekingalpha.com/symbol/PRVB' title='Provention Bio, Inc.'>PRVB</a>) <font color=\"red\">-10%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418221\" data-linked=\"Aduro BioTech and PolarityTE among healthcare gainers; Biocept and Fortress Biotech among losers\" data-tweet=\"$ADIL $ADIL $MOTS - Aduro BioTech and PolarityTE among healthcare gainers; Biocept and Fortress Biotech among losers https://seekingalpha.com/news/3418221-aduro-biotech-and-polarityte-among-healthcare-gainers-biocept-and-fortress-biotech-among?source=tweet\" data-url=\"https://seekingalpha.com/news/3418221-aduro-biotech-and-polarityte-among-healthcare-gainers-biocept-and-fortress-biotech-among\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418217\" data-ts=\"1545234340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MSFT\" target=\"_blank\">MSFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418217-mellanoxplus-4-on-report-of-microsoft-acquisition-interest\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mellanox +4% on report of Microsoft acquisition interest</a></h4><ul><li>Microsoft (<a href='https://seekingalpha.com/symbol/MSFT' title='Microsoft Corporation'>MSFT</a> <font color='green'>+1.5%</font>) is considering acquiring Mellanox (NASDAQ:<a href='https://seekingalpha.com/symbol/MLNX' title='Mellanox Technologies, Ltd.'>MLNX</a>), according to The Marker via <a href=\"https://www.timesofisrael.com/microsoft-mulls-acquisition-of-israeli-chipmaker-mellanox-report/\" target=\"_blank\">The Times of Israel</a>.</li><li>Goldman Sachs is reportedly managing negotiations.</li><li>Microsoft is a client of Mellanox's server and storage switch solutions.</li><li>As always with deal rumors, take details with a grain of salt.</li><li>Last month, CNBC <a href=\"https://www.cnbc.com/2018/11/07/xilinx-working-with-barclays-to-buy-mellanox-possible-december-deal.html\" target=\"_blank\">reported</a> that Xilinx (<a href='https://seekingalpha.com/symbol/XLNX' title='Xilinx, Inc.'>XLNX</a> <font color='green'>+0.2%</font>) was working with Barclays on a potential Mellanox acquisition.</li><li>Mellanox shares are <font color=\"green\">up 4.3%</font> to $92.72.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418217\" data-linked=\"Mellanox +4% on report of Microsoft acquisition interest\" data-tweet=\"$MSFT $MSFT $MLNX - Mellanox +4% on report of Microsoft acquisition interest https://seekingalpha.com/news/3418217-mellanoxplus-4-on-report-of-microsoft-acquisition-interest?source=tweet\" data-url=\"https://seekingalpha.com/news/3418217-mellanoxplus-4-on-report-of-microsoft-acquisition-interest\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418209\" data-ts=\"1545233554\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/JBL\" target=\"_blank\">JBL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418209-analysts-adjust-jabil-targets-after-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts adjust Jabil targets after earnings</a></h4><ul><li>RBC Capital maintains a Sector Perform rating on Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>) but raises the target from $29 to $30.</li><li>Analyst Amit Daryanani views the earnings results as strong but notes that Q2 guidance implies a 40 percentage point Y/Y decrease decline in operating margins due to new business costs.</li><li>More action: Stifel maintains a Hold rating on Jabil and lowers the target from $30 to $27 citing lower multiples and new program ramp risks.</li><li>Source: StreetAccount.</li><li>Jabil shares are <font color=\"green\">up 6.8%</font> to $23.75.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418024-jabil-plus-10-percent-q1-beats-upside-revenue-guide\" target=\"_blank\">Jabil +10% on Q1 beats, upside revenue guide</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418209\" data-linked=\"Analysts adjust Jabil targets after earnings\" data-tweet=\"$JBL - Analysts adjust Jabil targets after earnings https://seekingalpha.com/news/3418209-analysts-adjust-jabil-targets-after-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3418209-analysts-adjust-jabil-targets-after-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:32 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418207\" data-ts=\"1545233518\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AIR\" target=\"_blank\">AIR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418207-aar-corporation-down-6-post-q2-results-lowers-fy-revenue-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AAR Corporation down 6% post Q2 results; lowers FY revenue guidance</a></h4><ul><li>AAR (<a href='https://seekingalpha.com/symbol/AIR' title='AAR Corporation'>AIR</a> <font color=\"red\">-6%</font>) reported Q2 sales growth of 17.3% Y/Y to $493.3M, due to continued growth in company\u2019s trading, distribution and programs activities.</li><li>Sales by segments: Aviation Services $462.9M (+18.2% Y/Y) and Expeditionary Services $30.4M (+5.2% Y/Y).</li><li>Commercial customer sales contribute 68% to total sales, and government and defense customer contribution was 32%.</li><li>Q2 Gross margin <font color=\"red\">declined by 94 bps</font> to 18.9% and operating margin <font color=\"red\">declined by 178 bps</font> to 3.4%.</li><li>SG&amp;A margin <font color=\"green\">declined by 160 bps </font>to 10%.</li><li>Adj. EBITDA increased 15.3% Y/Y to $40.8M and margin <font color=\"red\">declined by 15 bps</font> to 8.3%.</li><li><strong>FY19 Guidance:</strong> Revenue $2-2.1B (prior $2.1-2.2B); Adj. EPS $2.5-2.8 and Adj. EBITDA $180-190M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417992-aar-beats-0_02-misses-revenue\" target=\"_blank\">AAR beats by $0.02, misses on revenue</a> (Dec. 18)</li><li><a href=\"https://seekingalpha.com/article/4229114-aar-corporation-air-ceo-john-holmes-q2-2019-results-earnings-call-transcript?part=single\" target=\"_blank\">Transcript</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3418207\" data-linked=\"AAR Corporation down 6% post Q2 results; lowers FY revenue guidance\" data-tweet=\"$AIR - AAR Corporation down 6% post Q2 results; lowers FY revenue guidance https://seekingalpha.com/news/3418207-aar-corporation-down-6-post-q2-results-lowers-fy-revenue-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3418207-aar-corporation-down-6-post-q2-results-lowers-fy-revenue-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418208\" data-ts=\"1545233469\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418208-crude-inventory-declines-slightly\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude inventory declines slightly</a></h4><ul>     <li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>: Crude <strong>-0.5M </strong>barrels vs. -2.4M consensus, -1.2M last week.</li> <li>Gasoline<strong> +1.8M</strong> barrels vs. +1.2M consensus, +2.1M last week.</li> <li>Distillates <strong>-4.2M </strong>barrels vs. +0.6M consensus, -1.5M last week.</li> <li>Futures <font color=\"green\">+2.21%</font> to $47.63.</li> <li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3418208\" data-linked=\"Crude inventory declines slightly\" data-tweet=\"$USO $OIL $UCO - Crude inventory declines slightly https://seekingalpha.com/news/3418208-crude-inventory-declines-slightly?source=tweet\" data-url=\"https://seekingalpha.com/news/3418208-crude-inventory-declines-slightly\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>49&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418202\" data-ts=\"1545232829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LRCX\" target=\"_blank\">LRCX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418202-chip-stocks-stable-after-micron-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Chip stocks stable after Micron earnings</a></h4><ul><li>Chip stocks aren't taking much of a hit from Micron's earnings report yesterday with Lam Research (<a href='https://seekingalpha.com/symbol/LRCX' title='Lam Research Corporation'>LRCX</a> <font color=\"green\">+1.4%</font>) and Applied Materials (<a href='https://seekingalpha.com/symbol/AMAT' title='Applied Materials, Inc.'>AMAT</a> <font color=\"green\">+1%</font>) reversing aftermarket losses. The Philadelphia Semiconductor Index is <font color=\"green\">up a slight 0.1%</font>.</li><li>Related semiconductor ETFs: <a href='https://seekingalpha.com/symbol/SOXL' title='Direxion Daily Semiconductor 3x Bull Shares ETF'>SOXL</a>, <a href='https://seekingalpha.com/symbol/SOXX' title='iShares PHLX SOX Semiconductor Sector Index ETF'>SOXX</a>, <a href='https://seekingalpha.com/symbol/SMH' title='VanEck Vectors Semiconductor ETF'>SMH</a>, <a href='https://seekingalpha.com/symbol/USD' title='ProShares Ultra Semiconductors ETF'>USD</a>, <a href='https://seekingalpha.com/symbol/PSI' title='Invesco Dynamic Semiconductors Portfolio ETF'>PSI</a>, <a href='https://seekingalpha.com/symbol/XSD' title='SPDR S&P Semiconductor ETF'>XSD</a>, <a href='https://seekingalpha.com/symbol/SOXS' title='Direxion Daily Semiconductor 3x Bear Shares ETF'>SOXS</a>, <a href='https://seekingalpha.com/symbol/SSG' title='ProShares UltraShort Semiconductors ETF'>SSG</a>, <a href='https://seekingalpha.com/symbol/FTXL' title='First Trust Nasdaq Semiconductor ETF'>FTXL</a>, <a href='https://seekingalpha.com/symbol/XTH' title='SPDR S&P Technology Hardware ETF'>XTH</a></li><li>Previously: <a href=\"https://seekingalpha.com/news/3418017-micron-minus-7-percent-mixed-q1-downside-guide-capex-cut\" target=\"_blank\">Micron -7% on mixed Q1, downside guide, capex cut</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418202\" data-linked=\"Chip stocks stable after Micron earnings\" data-tweet=\"$LRCX $LRCX $AMAT - Chip stocks stable after Micron earnings https://seekingalpha.com/news/3418202-chip-stocks-stable-after-micron-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3418202-chip-stocks-stable-after-micron-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418196\" data-ts=\"1545232389\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SCS\" target=\"_blank\">SCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418196-steelcase-reports-q3-results-sharesplus-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Steelcase reports Q3 results; shares +2%</a></h4><ul><li>Steelcase (<a href='https://seekingalpha.com/symbol/SCS' title='Steelcase Inc.'>SCS</a> <font color=\"green\">+2%</font>) reports <a href=\"https://seekingalpha.com/pr/17361999-steelcase-reports-third-quarter-fiscal-2019-results\" target=\"_blank\">Q3</a> sales increase 16.7% Y/Y to $901M &amp; 13% Y/Y on an organic basis led by all growth across Americas &amp; EMEA due to strong project business from both large and small customers; orders increases 10% Y/Y.</li><li>Sales by segment: Americas: $638.6M (+15.5% Y/Y &amp; organic +12%); EMEA: $170.9M (+21.1% Y/Y &amp; organic +12%) &amp; Others: $91.5M (+17% Y/Y &amp; organic +20%)</li><li>Gross margin <font color=\"red\">declined 160 bps</font> to 30.9%; <font color=\"red\">decreased by 190 bps</font> in the Americas &amp; EMEA <font color=\"red\">decreased by 60 bps</font>.</li><li>Operating margin <font color=\"green\">expanded 30 bps</font> to 5%.</li><li>The company's acquisition of Orangebox Group was completed on September 19, 2018, and was funded by $78.9M of borrowings under the company's global committed bank facility.</li><li>Total liquidity aggregated $205.7M and total debt was $321.4M.</li><li>Declared a quarterly cash dividend of $0.135/share payabe on or before January 14, 2019.</li><li><b>Q4 Outlook</b>: Sales of ~$860M-885M; expected organic growth of 9-12%; EPS $0.24-0.28.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417997-steelcase-beats-0_06-beats-revenue\" target=\"_blank\">Steelcase beats by $0.06, beats on revenue</a> (Dec. 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3417998-steelcase-declares-0_135-dividend\" target=\"_blank\">Steelcase declares $0.135 dividend</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418196\" data-linked=\"Steelcase reports Q3 results; shares +2%\" data-tweet=\"$SCS - Steelcase reports Q3 results; shares +2% https://seekingalpha.com/news/3418196-steelcase-reports-q3-results-sharesplus-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3418196-steelcase-reports-q3-results-sharesplus-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418195\" data-ts=\"1545232194\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GDDY\" target=\"_blank\">GDDY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418195-godaddyplus-3-on-citi-start-buy\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GoDaddy +3% on Citi start at Buy</a></h4><ul><li>Citi transfers GoDaddy (NYSE:<a href='https://seekingalpha.com/symbol/GDDY' title='GoDaddy Inc.'>GDDY</a>) coverage to analyst Nicholas Jones who gives the stock a Buy rating and $82 target.</li><li>The analyst cites GDDY's healthy FCF and capital allocation strategy.</li><li>Jones thinks GoDaddy can increase ARPU to $230+ by 2029 from about $150 this year.</li><li>Source: Bloomberg First Word.</li><li>GoDaddy shares are <font color=\"green\">up 3%</font> to $63.85.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418195\" data-linked=\"GoDaddy +3% on Citi start at Buy\" data-tweet=\"$GDDY - GoDaddy +3% on Citi start at Buy https://seekingalpha.com/news/3418195-godaddyplus-3-on-citi-start-buy?source=tweet\" data-url=\"https://seekingalpha.com/news/3418195-godaddyplus-3-on-citi-start-buy\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418193\" data-ts=\"1545231827\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WIX\" target=\"_blank\">WIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418193-wixplus-3_5-on-citi-start\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wix +3.5% on Citi start</a></h4><ul><li>Citi starts Wix (NASDAQ:<a href='https://seekingalpha.com/symbol/WIX' title='Wix.com'>WIX</a>) at Buy with a $116 target.</li><li>Analyst Nicholas Jones expects Wix revenue and user growth to be in the \u201cdouble digits for the foreseeable future.\u201d</li><li>The analyst thinks Wix can improve ARPU to $200 by 2029 from $146 in 2018.</li><li>Source: Bloomberg First Word.</li><li>Wix shares are <font color=\"green\">up 3.5%</font> to $88.68.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418193\" data-linked=\"Wix +3.5% on Citi start\" data-tweet=\"$WIX - Wix +3.5% on Citi start https://seekingalpha.com/news/3418193-wixplus-3_5-on-citi-start?source=tweet\" data-url=\"https://seekingalpha.com/news/3418193-wixplus-3_5-on-citi-start\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418189\" data-ts=\"1545231557\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AVGR\" target=\"_blank\">AVGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418189-avinger-up-9-on-positive-pantheris-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Avinger up 9% on positive Pantheris data</a></h4><ul><li>Nano cap Avinger (<a href='https://seekingalpha.com/symbol/AVGR' title='Avinger'>AVGR</a> <font color=\"green\">+8.6%</font>) is up on below-average volume following its <a href=\"https://seekingalpha.com/pr/17362306-avinger-announces-preliminary-analysis-results-scan-clinical-study\" target=\"_blank\">announcement </a>of post-market data supporting the value proposition of its <a href=\"http://avinger.com/devices/pantheris/\" target=\"_blank\">Pantheris </a>image-guided atherectomy system.</li><li>The study, SCAN, showed that optical coherence tomography &#40;OCT&#41; imaging with Pantheris was equivalent or superior to intravascular ultrasound &#40;IVUS&#41; on all parameters.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418189\" data-linked=\"Avinger up 9% on positive Pantheris data\" data-tweet=\"$AVGR - Avinger up 9% on positive Pantheris data https://seekingalpha.com/news/3418189-avinger-up-9-on-positive-pantheris-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3418189-avinger-up-9-on-positive-pantheris-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418188\" data-ts=\"1545231199\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHAK\" target=\"_blank\">SHAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418188-shake-shackplus-2-on-jefferies-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Shake Shack +2% on Jefferies upgrade</a></h4><ul><li>Jefferies analyst Andrew Barish upgrades Shake Shack (NYSE:<a href='https://seekingalpha.com/symbol/SHAK' title='Shake Shack'>SHAK</a>) from Underperform to Hold and reiterates the $45 price target.</li><li>Barish calls SHAK a \"cult brand with impressive unit growth\" that's balanced by comparable sales and margin erosion.</li><li>Barish prefers restaurant industry stocks with clear comp drivers. Top picks: (<a href='https://seekingalpha.com/symbol/SBUX' title='Starbucks Corporation'>SBUX</a> <font color='green'>+1.2%</font>), (<a href='https://seekingalpha.com/symbol/MCD' title='McDonald&#39;s Corporation'>MCD</a> <font color='green'>+1.2%</font>), (<a href='https://seekingalpha.com/symbol/CMG' title='Chipotle Mexican Grill, Inc.'>CMG</a> <font color='green'>+0.4%</font>), (<a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> <font color='green'>+1.3%</font>).</li><li>Source: Bloomberg First Word.</li><li>SHAK shares are<font color=\"green\"> up 2%</font> to $45.93.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418188\" data-linked=\"Shake Shack +2% on Jefferies upgrade\" data-tweet=\"$SHAK $SHAK $SBUX - Shake Shack +2% on Jefferies upgrade https://seekingalpha.com/news/3418188-shake-shackplus-2-on-jefferies-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3418188-shake-shackplus-2-on-jefferies-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418186\" data-ts=\"1545231144\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IFRX\" target=\"_blank\">IFRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418186-inflarx-on-go-mid-stage-vasculitis-study-in-europe-for-ifxminus-1-shares-up-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">InflaRx on go with mid-stage vasculitis study in Europe for IFX-1; shares up 2%</a></h4><ul><li>European regulators have <a href=\"https://seekingalpha.com/pr/17362594-inflarx-receives-european-approval-initiate-phase-ii-clinical-trial-ifxminus-1-anca\" target=\"_blank\">signed off</a> on a Phase 2 clinical trial evaluating InflaRx N.V.'s (<a href='https://seekingalpha.com/symbol/IFRX' title='InflaRx N.V.'>IFRX</a> <font color=\"green\">+2.4%</font>) lead candidate IFX-1, an anti-human <a href=\"https://www.inflarx.de/Home/Research---Development/About-C5A.html\" target=\"_blank\">complement factor C5</a> antibody, in patients with a rare autoimmune disorder called ANCA-associated vasculitis &#40;AAV&#41;.</li><li>The 80-subject study should launch next quarter.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418186\" data-linked=\"InflaRx on go with mid-stage vasculitis study in Europe for IFX-1; shares up 2%\" data-tweet=\"$IFRX - InflaRx on go with mid-stage vasculitis study in Europe for IFX-1; shares up 2% https://seekingalpha.com/news/3418186-inflarx-on-go-mid-stage-vasculitis-study-in-europe-for-ifxminus-1-shares-up-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3418186-inflarx-on-go-mid-stage-vasculitis-study-in-europe-for-ifxminus-1-shares-up-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418185\" data-ts=\"1545230746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RRGB\" target=\"_blank\">RRGB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418185-red-robinminus-1_7-jefferies-questions-turnaround\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Red Robin -1.7% as Jefferies questions turnaround</a></h4><ul><li>Jefferies downgrades Red Robin (NASDAQ:<a href='https://seekingalpha.com/symbol/RRGB' title='Red Robin Gourmet Burgers, Inc.'>RRGB</a>) from Buy to Hold and cuts the target from $45 to $34 on the belief that a potential turnaround is \"still a ways off.\"</li><li>Analyst Andrew Barish says a return to positive comparable sales is possible, but visibility isn't clear with competitive pressures in casual dining expected to continue into next year.</li><li>Source: Bloomberg First Word.</li><li>Red Robin shares are <font color=\"red\">down 1.7%</font> to $30.60.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418185\" data-linked=\"Red Robin -1.7% as Jefferies questions turnaround\" data-tweet=\"$RRGB - Red Robin -1.7% as Jefferies questions turnaround https://seekingalpha.com/news/3418185-red-robinminus-1_7-jefferies-questions-turnaround?source=tweet\" data-url=\"https://seekingalpha.com/news/3418185-red-robinminus-1_7-jefferies-questions-turnaround\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418182\" data-ts=\"1545230718\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ABM\" target=\"_blank\">ABM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418182-abm-industriesplus-5_3-post-q4-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ABM Industries +5.3% post Q4 results</a></h4><ul><li>ABM Industries (<a href='https://seekingalpha.com/symbol/ABM' title='ABM Industries Incorporated'>ABM</a> <font color=\"green\">+5.3%</font>) reports <a href=\"https://seekingalpha.com/pr/17362034-abm-industries-announces-fourth-quarter-full-year-2018-financial-results\" target=\"_blank\">Q4</a> revenue growth of 10.7% Y/Y to $1.65B.</li><li>Segment revenue: Business &amp; Industry of $737.1M (+7.8% Y/Y); Aviation $265.5M (-0.7% Y/Y); Technology &amp; Manufacturing $234.2M (+15.4% Y/Y); Education $214M (+30.8% Y/Y); Technical Solutions $131.4M (+14.8% Y/Y) &amp; Healthcare $66.6M (+1% Y/Y).</li><li>For fiscal 2018, organic growth was 4.0% primarily driven by the Business &amp; Industry, Technical Solutions and Technology &amp; Manufacturing segments.</li><li>Adj. EBITDA margin<font color=\"green\"> increased 72 bps</font> to 5.45%.</li><li>Adj. income from continuing operations increased 65.1% Y/Y to $38.8M.</li><li>Net cash provided by operating activities increased $93.3M, reflects better working capital management.</li><li>Total debt, including standby letters of credit, was $1.1B; Total debt to Adj. EBITDA was ~3.2x &amp; the company paid a quarterly cash dividend of $0.175 per common share for a total distribution of $11.5M.</li><li><b>2019 Outlook:</b> GAAP EPS of $1.65-1.80; Adj. EPS of $1.90-2.05.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418007-abm-industries-beats-0_02-misses-revenue\" target=\"_blank\">ABM Industries beats by $0.02, misses on revenue</a> (Dec. 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418028-abm-industries-declares-0_18-dividend\" target=\"_blank\">ABM Industries declares $0.18 dividend</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418182\" data-linked=\"ABM Industries +5.3% post Q4 results\" data-tweet=\"$ABM - ABM Industries +5.3% post Q4 results https://seekingalpha.com/news/3418182-abm-industriesplus-5_3-post-q4-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3418182-abm-industriesplus-5_3-post-q4-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418178\" data-ts=\"1545230045\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EIGR\" target=\"_blank\">EIGR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418178-fda-grants-accelerated-review-status-for-eiger-bios-lonafarnib-for-rare-accelerated-aging\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA grants accelerated review status for Eiger Bio&#39;s lonafarnib for rare accelerated aging disorder</a></h4><ul><li>Eiger BioPharmaceuticals (<a href='https://seekingalpha.com/symbol/EIGR' title='Eiger BioPharmaceuticals, Inc.'>EIGR</a> <font color=\"green\">+0.4%</font>) is up out of the gate this morning on the heels of the FDA's <a href=\"https://seekingalpha.com/pr/17362443-eiger-announces-breakthrough-therapy-designation-granted-fda-lonafarnib-progeria-progeroid\" target=\"_blank\">designation </a>of Breakthrough Therapy status for lonafarnib for the treatment of Hutchinson-Gilford progeria syndrome (HGPS or <a href=\"https://www.mayoclinic.org/diseases-conditions/progeria/symptoms-causes/syc-20356038\" target=\"_blank\">Progeria</a>) and progeroid laminopathies, a ultra-rare inherited disorder in children characterized by accelerated aging.</li><li>Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418178\" data-linked=\"FDA grants accelerated review status for Eiger Bio&#39;s lonafarnib for rare accelerated aging disorder\" data-tweet=\"$EIGR - FDA grants accelerated review status for Eiger Bio&#39;s lonafarnib for rare accelerated aging disorder https://seekingalpha.com/news/3418178-fda-grants-accelerated-review-status-for-eiger-bios-lonafarnib-for-rare-accelerated-aging?source=tweet\" data-url=\"https://seekingalpha.com/news/3418178-fda-grants-accelerated-review-status-for-eiger-bios-lonafarnib-for-rare-accelerated-aging\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:34 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418175\" data-ts=\"1545229610\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PAYX\" target=\"_blank\">PAYX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418175-paychex-sees-fy2019-adjusted-eps-up-11minus-12\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Paychex sees FY2019 adjusted EPS up 11%-12%</a></h4><ul><li>Paychex (NASDAQ:<a href='https://seekingalpha.com/symbol/PAYX' title='Paychex, Inc.'>PAYX</a>) sees fiscal 2019 adjusted EPS up 11%-12%, up from previous guidance of up ~11%.</li><li>Sees FY2019 investment income of $10M-$15M vs. previous guidance of ~$15M.</li><li><a href=\"https://seekingalpha.com/pr/17362581-paychex-inc-reports-second-quarter-results\" target=\"_blank\">Q2 EPS of 65 cents</a> beats consensus estimate of 63 cents.</li><li>Q2 total service revenue up 7% to $840.6M.</li><li>Interest on funds held for clients increased 31% to $18.3M.</li><li><a href=\"https://www.paychex.com/investors\" target=\"_blank\">Conference call</a> 9:30 AM ET.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418136-paychex-beats-0_02-revenue-line\" target=\"_blank\">Paychex beats by $0.02,  revenue in-line</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418175\" data-linked=\"Paychex sees FY2019 adjusted EPS up 11%-12%\" data-tweet=\"$PAYX - Paychex sees FY2019 adjusted EPS up 11%-12% https://seekingalpha.com/news/3418175-paychex-sees-fy2019-adjusted-eps-up-11minus-12?source=tweet\" data-url=\"https://seekingalpha.com/news/3418175-paychex-sees-fy2019-adjusted-eps-up-11minus-12\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418172\" data-ts=\"1545229364\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYEN\" target=\"_blank\">EYEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418172-eyenovia-down-9-premarket-on-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eyenovia down 9% premarket on equity offering</a></h4><ul><li>Thinly traded nano cap Eyenovia (NASDAQ:<a href='https://seekingalpha.com/symbol/EYEN' title='Eyenovia, Inc.'>EYEN</a>) is down <font color=\"red\">9%</font> premarket on more than triple normal volume, albeit on turnover of only 57K shares, in reaction to its <a href=\"https://seekingalpha.com/pr/17362821-eyenovia-prices-public-offering-common-stock\" target=\"_blank\">public offering</a> of 1.2M common shares at $2.45 per share.</li><li>Underwriters over-allotment is an additional 180K shares.</li><li>Yesterday's close was $2.91.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418172\" data-linked=\"Eyenovia down 9% premarket on equity offering\" data-tweet=\"$EYEN - Eyenovia down 9% premarket on equity offering https://seekingalpha.com/news/3418172-eyenovia-down-9-premarket-on-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3418172-eyenovia-down-9-premarket-on-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:22 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418169\" data-ts=\"1545229158\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GE\" target=\"_blank\">GE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418169-ge-catches-another-upgrade-sharesplus-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE catches another upgrade; shares +4%</a></h4><ul><li>\"After ten years on the sidelines we are upgrading to Buy,\" <a href=\"https://ibankcoin.com/flyblog/2018/12/19/ge-catches-upgrade-shares-rally/#sthash.4eUhsN1l.dpbs\" target=\"_blank\">says Vertical Research's Jeff Sprague</a>. \"We see a path to create equity value.\"</li><li>He reminds that it took 20 years for General Electric (NYSE:<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a>) to \"dig this hole,\" and it'll take more than a couple of years to climb out of it.</li><li>\"While the work ahead is still hard, we think the lack of investor confidence will slowly subside.\"</li><li>Shares <font color=\"green\">+4.1%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3418169\" data-linked=\"GE catches another upgrade; shares +4%\" data-tweet=\"$GE - GE catches another upgrade; shares +4% https://seekingalpha.com/news/3418169-ge-catches-another-upgrade-sharesplus-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3418169-ge-catches-another-upgrade-sharesplus-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418166\" data-ts=\"1545228895\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADRO\" target=\"_blank\">ADRO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418166-gsk-riot-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GSK, RIOT among premarket gainers</a></h4><ul><li>Aduro BioTech (NASDAQ:<a href='https://seekingalpha.com/symbol/ADRO' title='Aduro Biotech'>ADRO</a>) <font color=\"green\">+21%</font> on <a href=\"https://seekingalpha.com/news/3418021-aduro-bio-licenses-cgas-sting-inhibitor-program-eli-lilly-shares-32-percent-hours\" target=\"_blank\">out-licenses</a> cGAS-STING inhibitor program to Eli Lilly.</li><li>Riot Blockchain (NASDAQ:<a href='https://seekingalpha.com/symbol/RIOT' title='Riot Blockchain, Inc.'>RIOT</a>) <font color=\"green\">+18%</font>.</li><li>Winnebago Industries (NYSE:<a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a>) <font color=\"green\">+10%</font> on Q1 <a href=\"https://seekingalpha.com/news/3418081-winnebago-beats-0_07-beats-revenue\" target=\"_blank\">earnings</a>.</li><li>Jabil (NYSE:<a href='https://seekingalpha.com/symbol/JBL' title='Jabil Inc.'>JBL</a>) <font color=\"green\">+10%</font> on Q1 <a href=\"https://seekingalpha.com/news/3417996-jabil-beats-0_02-beats-revenue\" target=\"_blank\">earnings</a>.</li><li>Adial Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/ADIL' title='ADial Pharmaceuticals, Inc'>ADIL</a>) <font color=\"green\">+10%</font> on <a href=\"https://seekingalpha.com/pr/17362683-adial-pharmaceuticals-announces-amendment-license-agreement-university-virginia-licensing-and\" target=\"_blank\">amending</a> its license agreement with the University of Virginia Patent Foundation.</li><li>Rent-A-Center (NASDAQ:<a href='https://seekingalpha.com/symbol/RCII' title='Rent-A-Center Inc.'>RCII</a>) <font color=\"green\">+8%</font> as B. Riley Financial <a href=\"https://seekingalpha.com/pr/17362414-b-riley-financial-issues-statement-regarding-rent-center-transaction\" target=\"_blank\">issues statement</a>.</li><li>Tilray (NASDAQ:<a href='https://seekingalpha.com/symbol/TLRY' title='Tilray, Inc.'>TLRY</a>) <font color=\"green\">+5%</font>.</li><li>GlaxoSmithKline plc (NYSE:<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a>) <font color=\"green\">+5%</font> as Pfizer and Glaxo to <a href=\"https://seekingalpha.com/news/3418062-glaxo-pfizer-merge-consumer-health-units\" target=\"_blank\">merge</a> consumer health unit.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418166\" data-linked=\"GSK, RIOT among premarket gainers\" data-tweet=\"$ADRO $ADRO $RIOT - GSK, RIOT among premarket gainers https://seekingalpha.com/news/3418166-gsk-riot-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3418166-gsk-riot-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418164\" data-ts=\"1545228694\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOC\" target=\"_blank\">BIOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418164-fdx-and-mu-among-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDX and MU among premarket losers</a></h4><ul><li>Biocept (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a>) <font color=\"red\">-18%</font> on <a href=\"https://seekingalpha.com/news/3418116-biocept-readies-downsized-equity-offering-shares-12-percent-premarket\" target=\"_blank\">announcing</a> downsized equity offering.</li><li>Eyenovia (NASDAQ:<a href='https://seekingalpha.com/symbol/EYEN' title='Eyenovia, Inc.'>EYEN</a>) <font color=\"red\">-9%</font> on <a href=\"https://seekingalpha.com/pr/17362821-eyenovia-prices-public-offering-common-stock\" target=\"_blank\">pricing</a> common stock offering.</li><li>FedEx (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/news/3417993-fedex-beats-0_09-beats-revenue\" target=\"_blank\">Q2 earnings</a>.</li><li>Micron Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) <font color=\"red\">-7%</font> on <a href=\"https://seekingalpha.com/news/3417991-micron-technology-beats-0_02-misses-revenue\" target=\"_blank\">Q1 earnings</a>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3418164\" data-linked=\"FDX and MU among premarket losers\" data-tweet=\"$BIOC $BIOC $EYEN - FDX and MU among premarket losers https://seekingalpha.com/news/3418164-fdx-and-mu-among-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3418164-fdx-and-mu-among-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418150\" data-ts=\"1545227356\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418150-allergan-down-3-premarket-on-suspended-sales-of-textured-breast-implants-in-europe\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allergan down 3% premarket on suspended sales of textured breast implants in Europe</a></h4><ul><li>Allergan (NYSE:<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a>) slips <font color=\"red\">3%</font> premarket on light volume in reaction to its <a href=\"https://seekingalpha.com/pr/17362601-allergan-suspends-sales-withdraws-supply-textured-breast-implants-european-markets\" target=\"_blank\">announcement</a> that it has suspended sales of textured breast implants and tissue expanders and withdrawing any remaining product supply in Europe. The action follows a compulsory recall request from a French regulatory authority after its CE Mark certification for the products expired.</li><li>The company takes issue with the request saying that there are no safety signals/concerns with the products and no scientific evidence that suggests otherwise. It plans to participate in a scientific forum in France in February to review and discuss the full range of data for textured breast implants. Its smooth implants are unaffected.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418150\" data-linked=\"Allergan down 3% premarket on suspended sales of textured breast implants in Europe\" data-tweet=\"$AGN - Allergan down 3% premarket on suspended sales of textured breast implants in Europe https://seekingalpha.com/news/3418150-allergan-down-3-premarket-on-suspended-sales-of-textured-breast-implants-in-europe?source=tweet\" data-url=\"https://seekingalpha.com/news/3418150-allergan-down-3-premarket-on-suspended-sales-of-textured-breast-implants-in-europe\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:49 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418148\" data-ts=\"1545227246\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RCII\" target=\"_blank\">RCII</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418148-rent-center-rating-raised-to-outperform-raymond-james\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rent-A-Center rating raised to Outperform at Raymond James</a></h4><ul><li>Rent-A-Center is up <font color=\"green\">8.3%</font> in premarket trading after Raymond James issues an outperform rating to the company with a PT of $16.</li><li>In other news, B. Riley <a href=\"https://seekingalpha.com/pr/17362414-b-riley-financial-issues-statement-regarding-rent-center-transaction\" target=\"_blank\">issues a statement</a> that Rent-A-Center's termination of Vintage       Capital agreement is invalid and Vintage Capital can enforce its rights.</li><li>The street is eyeing the merger and Vintage says that the Timing Agreement implied a Jan. extension.</li><li>Source: Bloomberg FW</li></ul><div class=\"tiny-share-widget\" data-id=\"3418148\" data-linked=\"Rent-A-Center rating raised to Outperform at Raymond James\" data-tweet=\"$RCII - Rent-A-Center rating raised to Outperform at Raymond James https://seekingalpha.com/news/3418148-rent-center-rating-raised-to-outperform-raymond-james?source=tweet\" data-url=\"https://seekingalpha.com/news/3418148-rent-center-rating-raised-to-outperform-raymond-james\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:47 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418145\" data-ts=\"1545227081\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NCS\" target=\"_blank\">NCS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418145-nci-building-gains-2_8-after-q4-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NCI Building gains 2.8% after Q4 beat</a></h4><ul><li>NCI Building (NYSE:<a href='https://seekingalpha.com/symbol/NCS' title='NCI Building Systems Inc.'>NCS</a>) <font color=\"green\">rises 2.8%</font> in premarket trading after <a href=\"https://seekingalpha.com/pr/17362382-nci-building-systems-reports-fourth-quarter-2018-fiscal-year-end-results\" target=\"_blank\">Q4 adjusted EPS</a> of 55 cents beats consensus estimate of 53 cents.</li><li>Q4 adjusted EBITDA increases 22% to $65.8M from a year ago; adjusted EBITDA margin widens to 11.5% from 11.0% a year ago.</li><li>Sales and adjusted operating income by segment:</li></ul><ol><li>Engineered building systems sales of $244.0M vs. $188.2M Y/Y; adjusted operating income $25.3M vs. $13.7M.</li><li>Metal components sales $187.6M vs. $181.3M; adjusted operating income $19.7M vs. $23.2M.</li><li>IMP sales $146.5M vs. $123.5M; adjusted operating income $21.4M vs. $15.7M.</li><li>Metal coil coating sales $117.3M vs. $98.6M; adjusted operating income $7.0M vs. $7.4M.</li></ol><ul><li>Ply Gem Q3 (quarter ending Sept. 29, 2018) consolidated net sales rose 21% to $119.7M Y/Y; adjusted EBITDA $101.3M, up $20.3M Y/Y.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418082-nci-building-systems-beats-0_02-beats-revenue\" target=\"_blank\">NCI Building Systems beats by $0.02, beats on revenue</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418145\" data-linked=\"NCI Building gains 2.8% after Q4 beat\" data-tweet=\"$NCS $CNR - NCI Building gains 2.8% after Q4 beat https://seekingalpha.com/news/3418145-nci-building-gains-2_8-after-q4-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3418145-nci-building-gains-2_8-after-q4-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:44 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418143\" data-ts=\"1545226989\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANIX\" target=\"_blank\">ANIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418143-anixa-biosciences-completes-pre-sub-meeting-fda-for-cchek-cancer-diagnostic-test\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Anixa Biosciences completes Pre-Sub meeting with FDA for Cchek cancer diagnostic test</a></h4><ul> <li>Anixa Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/ANIX' title='Anixa Biosciences, Inc.'>ANIX</a>) has <a href=\"https://seekingalpha.com/pr/17362355-anixa-biosciences-announces-completion-pre-sub-meeting-fda-cchek-cancer-diagnostic-test\" target=\"_blank\">completed</a> a Pre-Submission (Pre-Sub) meeting with the FDA on December 17.</li>                  <li>The meeting was focused on discussing Anixa's Cchek test, an artificial intelligence based liquid biopsy for the early detection of cancer.</li>  <li>Anixa Biosciences expects the official minutes of the Pre-Sub meeting to be available in January.  On January 24, 2019 Anixa plans to hold a conference call where it will discuss the commercialization path and timeline for Cchek-Prostate, as well as an update on its CAR-T therapeutics program.</li><li>Shares are up <font color=\"green\">2%</font> premarket.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3418143\" data-linked=\"Anixa Biosciences completes Pre-Sub meeting with FDA for Cchek cancer diagnostic test\" data-tweet=\"$ANIX - Anixa Biosciences completes Pre-Sub meeting with FDA for Cchek cancer diagnostic test https://seekingalpha.com/news/3418143-anixa-biosciences-completes-pre-sub-meeting-fda-for-cchek-cancer-diagnostic-test?source=tweet\" data-url=\"https://seekingalpha.com/news/3418143-anixa-biosciences-completes-pre-sub-meeting-fda-for-cchek-cancer-diagnostic-test\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418133\" data-ts=\"1545225888\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBY\" target=\"_blank\">BBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418133-best-buy-advnaces-on-moffett-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Best Buy advnaces on Moffett upgrade</a></h4><ul><li>Moffett Nathanson <a href=\"https://www.cnbc.com/2018/12/19/stocks-making-the-biggest-moves-premarket-gis-uaa-fdx-fb-jnj--more.html\" target=\"_blank\">upgraded</a> the electronics retailer to Neutral from Sell, noting a strong holiday season and the 30% drop in the stock over the past three months.</li><li><a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a> <font color=\"green\">+1%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3418133\" data-linked=\"Best Buy advnaces on Moffett upgrade\" data-tweet=\"$BBY - Best Buy advnaces on Moffett upgrade https://seekingalpha.com/news/3418133-best-buy-advnaces-on-moffett-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3418133-best-buy-advnaces-on-moffett-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:24 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418132\" data-ts=\"1545225784\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GIS\" target=\"_blank\">GIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418132-general-millsplus-4-after-mixed-q2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">General Mills +4% after mixed Q2</a></h4><ul><li>General Mills (NYSE:<a href='https://seekingalpha.com/symbol/GIS' title='General Mills, Inc.'>GIS</a>)<font color=\"green\"> gains 4%</font> premarket on Q2 results that beat EPS estimates but missed on revenue despite a 5% Y/Y growth driven by the Blue Buffalo acquisition.</li><li>FY19 guidance reaffirmed with revenue of $17.16B to $17.31B (might not be comparable to $17.06B consensus) and EPS of $3.02 to $3.11 (consensus: $3.06).</li><li><a href=\"https://seekingalpha.com/pr/17362378-general-mills-reports-fiscal-2019-second-quarter-results-reaffirms-full-year-guidance\" target=\"_blank\">Press release</a>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418080-general-mills-beats-0_04-misses-revenue\" target=\"_blank\">General Mills beats by $0.04, misses on revenue</a> (Dec. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418132\" data-linked=\"General Mills +4% after mixed Q2\" data-tweet=\"$GIS - General Mills +4% after mixed Q2 https://seekingalpha.com/news/3418132-general-millsplus-4-after-mixed-q2?source=tweet\" data-url=\"https://seekingalpha.com/news/3418132-general-millsplus-4-after-mixed-q2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>45&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418130\" data-ts=\"1545225629\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UAA\" target=\"_blank\">UAA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418130-atlantic-equities-sours-on-under-armour\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Atlantic Equities sours on Under Armour</a></h4><ul><li>Under Armour (NYSE:<a href='https://seekingalpha.com/symbol/UAA' title='Under Armour, Inc.'>UAA</a>) <font color=\"red\">-3%</font> premarket after the athletic apparel maker was <a href=\"https://www.cnbc.com/2018/12/19/stocks-making-the-biggest-moves-premarket-gis-uaa-fdx-fb-jnj--more.html\" target=\"_blank\">downgraded</a> to Underweight from Neutral at Atlantic Equities.</li><li>The firm said UAA was taking a more disciplined approach to growth, which will support the health of the brand but will also result in slower growth than previously expected.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418130\" data-linked=\"Atlantic Equities sours on Under Armour\" data-tweet=\"$UAA - Atlantic Equities sours on Under Armour https://seekingalpha.com/news/3418130-atlantic-equities-sours-on-under-armour?source=tweet\" data-url=\"https://seekingalpha.com/news/3418130-atlantic-equities-sours-on-under-armour\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418129\" data-ts=\"1545225623\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FGEN\" target=\"_blank\">FGEN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418129-fibrogen-up-4-premarket-citi-bullish-on-roxadustat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FibroGen up 4% premarket; Citi bullish on roxadustat</a></h4><ul><li>FibroGen (NASDAQ:<a href='https://seekingalpha.com/symbol/FGEN' title='FibroGen'>FGEN</a>) is up <font color=\"green\">4%</font> premarket on light volume following yesterday's <a href=\"https://seekingalpha.com/news/3417770-fibrogens-roxadustat-okd-china-ckd-patients-dialysis\" target=\"_blank\">approval </a>of roxadustat in China.</li><li>This morning, Citigroup upgraded the stock to Buy with a $71 (80% upside) price target. Analyst Joel Beatty is bullish about an FDA nod for the drug adding that non-dialysis use represents the bulk of the market opportunity. His model assumes a price of $10K in the non-dialysis setting compared to ~4.5K in dialysis. He also cites a CMS policy suggesting that new drugs will be covered via an add-on payment adjustment for two years which should stoke demand.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418129\" data-linked=\"FibroGen up 4% premarket; Citi bullish on roxadustat\" data-tweet=\"$FGEN - FibroGen up 4% premarket; Citi bullish on roxadustat https://seekingalpha.com/news/3418129-fibrogen-up-4-premarket-citi-bullish-on-roxadustat?source=tweet\" data-url=\"https://seekingalpha.com/news/3418129-fibrogen-up-4-premarket-citi-bullish-on-roxadustat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418125\" data-ts=\"1545225353\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSY\" target=\"_blank\">HSY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418125-big-upgrade-for-hershey-bofa-merrill\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Big upgrade for Hershey at BofA/Merrill</a></h4><ul><li>The chocolate maker <a href=\"https://www.cnbc.com/2018/12/19/stocks-making-the-biggest-moves-premarket-gis-uaa-fdx-fb-jnj--more.html\" target=\"_blank\">received</a> a double upgrade from Bank of America/Merrill Lynch to Buy from Underperform, saying investments made by Hershey (NYSE:<a href='https://seekingalpha.com/symbol/HSY' title='The Hershey Company'>HSY</a>) this year and in 2017 should result in improved organic sales and operating profit growth in 2019.</li><li>HSY <font color=\"green\">+1.5%</font> premarket</li></ul><div class=\"tiny-share-widget\" data-id=\"3418125\" data-linked=\"Big upgrade for Hershey at BofA/Merrill\" data-tweet=\"$HSY - Big upgrade for Hershey at BofA/Merrill https://seekingalpha.com/news/3418125-big-upgrade-for-hershey-bofa-merrill?source=tweet\" data-url=\"https://seekingalpha.com/news/3418125-big-upgrade-for-hershey-bofa-merrill\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418118\" data-ts=\"1545224918\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MU\" target=\"_blank\">MU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418118-analysts-downgrade-micron-on-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Analysts downgrade Micron on earnings</a></h4><ul><li>Needham<a href=\"https://www.streetinsider.com/Analyst+Comments/Needham+%26+Company+Downgrades+Micron+Technology+%28MU%29+to+Hold/14937309.html\" target=\"_blank\"> downgrades </a>Micron (NASDAQ:<a href='https://seekingalpha.com/symbol/MU' title='Micron Technology Inc.'>MU</a>) from Strong Buy to Hold after earnings.</li><li>Analyst Rajvindra Gill says the firm is concerned demand conditions could worsen and put more pressure on margins.</li><li>Gill: \"While we are hesitant about downgrading at this valuation level, we believe the overall demand environment will remain murky for at least the next six months and therefore we move to the sidelines.\"</li><li>More action: RBC Capital <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+RBC+Capital+Downgrades+Micron+Technology+%28MU%29+to+Sector+Perform/14936486.html\" target=\"_blank\">downgrades</a> from Outperform to Sector Perform and lowers the price target from $59 to $40, a 17% upside to yesterday's close.</li><li>Analyst Amit Daryanani cites inventory and demand risks, node transitions, and operating expense levels. The firm sees \"sizable risk\" for revenue, gross margins, and EPS reductions for the next two to three quarters.</li><li>WSJ's <a href=\"https://www.wsj.com/articles/micron-brings-back-painful-memories-11545182872\" target=\"_blank\">Heard on the Street</a> column is out negative on MU citing the Q2 revenue guidance, which represents the largest Q/Q drop in a decade at the midpoint, and the FY capex cut that suggests the company doesn't expect things to improve soon.</li><li>Micron shares are <font color=\"red\">down 8.2%</font> premarket to $31.33.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418017-micron-minus-7-percent-mixed-q1-downside-guide-capex-cut\" target=\"_blank\">Micron -7% on mixed Q1, downside guide, capex cut</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418118\" data-linked=\"Analysts downgrade Micron on earnings\" data-tweet=\"$MU - Analysts downgrade Micron on earnings https://seekingalpha.com/news/3418118-analysts-downgrade-micron-on-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3418118-analysts-downgrade-micron-on-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:08 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>126&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418116\" data-ts=\"1545224706\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOC\" target=\"_blank\">BIOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418116-biocept-readies-downsized-equity-offering-shares-down-12-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biocept readies downsized equity offering; shares down 12% premarket</a></h4><ul><li>Biocept (NASDAQ:<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a>) has filed <a href=\"https://www.sec.gov/Archives/edgar/data/1044378/000156459018031070/bioc-s1a.htm\" target=\"_blank\">prospectus </a>for a public offering of ~5.3M shares of common stock and warrants to purchase up to the same number of shares at an assumed combined price of $1.14.</li><li>Several weeks ago, it filed for an offering of ~9.7M shares plus warrants.</li><li>Shares are down <font color=\"red\">12%</font> premarket on average volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418116\" data-linked=\"Biocept readies downsized equity offering; shares down 12% premarket\" data-tweet=\"$BIOC - Biocept readies downsized equity offering; shares down 12% premarket https://seekingalpha.com/news/3418116-biocept-readies-downsized-equity-offering-shares-down-12-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3418116-biocept-readies-downsized-equity-offering-shares-down-12-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:05 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418115\" data-ts=\"1545224637\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXP\" target=\"_blank\">AXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418115-amexminus-1_2-in-premarket-bofaml-steps-to-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AmEx -1.2% in premarket as BofAML steps to sidelines</a></h4><ul><li>American Express (NYSE:<a href='https://seekingalpha.com/symbol/AXP' title='American Express Company'>AXP</a>) <font color=\"red\">slips 1.2%</font> in premarket trading after Bank of America Merrill Lynch <a href=\"https://www.cnbc.com/2018/12/19/american-express-downgraded-by-bank-of-america-its-been-a-good-run.html?__source=twitter%7Cmain\" target=\"_blank\">cut its rating</a> on the credit-card issuer to neutral from buy, saying it wouldn't be surprised if investors sell the stock after recent out-performance.</li><li>\"Given the broader market volatility and elevated uncertainty relating to the macro backdrop, we anticipate weaker sentiment,\" writes analyst Kenneth Bruce in a note.</li><li>Price target cut to $115 from $125.</li><li>Source: CNBC.</li><li><a href=\"https://seekingalpha.com/symbol/AXP/earnings/analyst_ratings\" target=\"_blank\">Analyst ratings</a>: 14 buys; 16 holds; 2 underperform/sells.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3413162-american-express-minus-1_0-percent-buckingham-downgrade\" target=\"_blank\">American Express -1.0% after Buckingham downgrade</a> (Nov. 29)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418115\" data-linked=\"AmEx -1.2% in premarket as BofAML steps to sidelines\" data-tweet=\"$AXP - AmEx -1.2% in premarket as BofAML steps to sidelines https://seekingalpha.com/news/3418115-amexminus-1_2-in-premarket-bofaml-steps-to-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3418115-amexminus-1_2-in-premarket-bofaml-steps-to-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418108\" data-ts=\"1545224267\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WGO\" target=\"_blank\">WGO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418108-winnebago-soars-20-after-strong-quarter\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Winnebago soars 20% after strong quarter</a></h4><ul><li>Winnebago (NYSE:<a href='https://seekingalpha.com/symbol/WGO' title='Winnebago Industries, Inc.'>WGO</a>) is <font color=\"green\">up just shy of 20%</font> <a href=\"https://seekingalpha.com/news/3418081-winnebago-beats-0_07-beats-revenue\" target=\"_blank\">after topping FQ1 estimates</a>, with CEO Michael Happe feeling it: \"We are very pleased with the strong start to our FY2019, resulting from our upward momentum within the North American RV business and the positive integration of our new marine division.\" He takes note of market share gains in RVs and expanded margins during quarter.</li><li>Peers on the move: Camping World (NYSE:<a href='https://seekingalpha.com/symbol/CWH' title='Camping World Holdings'>CWH</a>) <font color=\"green\">+1.2%</font>, Thor Industries (NYSE:<a href='https://seekingalpha.com/symbol/THO' title='Thor Industries, Inc.'>THO</a>) <font color=\"green\">+2.4%</font>. Others include: LCI Industries (NYSE:<a href='https://seekingalpha.com/symbol/LCII' title='LCI Industries'>LCII</a>) and Brunswick (NYSE:<a href='https://seekingalpha.com/symbol/BC' title='Brunswick Corporation'>BC</a>).</li></ul><div class=\"tiny-share-widget\" data-id=\"3418108\" data-linked=\"Winnebago soars 20% after strong quarter\" data-tweet=\"$WGO $WGO $CWH - Winnebago soars 20% after strong quarter https://seekingalpha.com/news/3418108-winnebago-soars-20-after-strong-quarter?source=tweet\" data-url=\"https://seekingalpha.com/news/3418108-winnebago-soars-20-after-strong-quarter\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418104\" data-ts=\"1545223853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FDX\" target=\"_blank\">FDX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418104-fedexs-jarring-guidance-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FedEx&#39;s &#39;jarring&#39; guidance cut</a></h4><ul><li>Concerns over the slowing global economy could be set to deepen next year, <a href=\"https://www.bloomberg.com/news/articles/2018-12-19/fedex-s-jarring-view-cut-seen-as-sign-of-worsening-global-woes?srnd=premium\" target=\"_blank\">says Morgan Stanley's Ravi Shanker</a> after digesting FedEx's (NYSE:<a href='https://seekingalpha.com/symbol/FDX' title='FedEx Corporation'>FDX</a>) whopping cuts to its 2019 forecasts.</li><li>Shanker: \"We recognize that global growth has slowed but we are very surprised by the magnitude of the headwind, which is what might be seen in a severe recession.\"</li><li>FedEx is <font color=\"red\">down 6.1%</font> premarket; <a href='https://seekingalpha.com/symbol/UPS' title='United Parcel Service, Inc.'>UPS</a> is <font color=\"red\">off 3%</font></li><li>Previously: <a href=\"https://seekingalpha.com/news/3418011-fedex-nearly-5-percent-cutting-guidance-ups-dips-alongside\" target=\"_blank\">FedEx off nearly 5% after cutting guidance; UPS dips alongside</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418104\" data-linked=\"FedEx&#39;s &#39;jarring&#39; guidance cut\" data-tweet=\"$FDX $FDX $UPS - FedEx&#39;s &#39;jarring&#39; guidance cut https://seekingalpha.com/news/3418104-fedexs-jarring-guidance-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3418104-fedexs-jarring-guidance-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418096\" data-ts=\"1545222622\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZIOP\" target=\"_blank\">ZIOP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418096-ziopharm-up-7-premarket-on-jv-in-asia\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ziopharm up 7% premarket on JV in Asia</a></h4><ul><li>ZIOPHARM Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/ZIOP' title='ZIOPHARM Oncology, Inc.'>ZIOP</a>) is up <font color=\"green\">7%</font> premarket on light volume following its <a href=\"https://seekingalpha.com/pr/17362338-ziopharm-oncology-triarm-therapeutics-establish-joint-venture-develop-commercialize-sleeping\" target=\"_blank\">announced </a>joint venture with TriArm Therapeutics for the development and commercialization of <em>Sleeping Beauty</em>-generated CAR-T therapies in China, Macau, Hong Kong, Taiwan and Korea.</li><li>TriArm, founded by venture fund Panacea Venture Healthcare, has operations in the U.S., Germany and China.</li><li>The new entity, owned 50/50 between ZIOP and TriArm, will do business as Eden BioCell. TriArm has committed up to $35M in initial capital.</li><li>In China, Taiwan and Korea, Eden BioCell will have own the rights to <em>Sleeping Beauty</em>-generated CAR-T therapies targeting CD19. TriArm will manage all clinical trials in China for Eden BioCell.</li><li>ZIOP will host a conference call this morning at 8:00 am ET to discuss the venture.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418096\" data-linked=\"Ziopharm up 7% premarket on JV in Asia\" data-tweet=\"$ZIOP - Ziopharm up 7% premarket on JV in Asia https://seekingalpha.com/news/3418096-ziopharm-up-7-premarket-on-jv-in-asia?source=tweet\" data-url=\"https://seekingalpha.com/news/3418096-ziopharm-up-7-premarket-on-jv-in-asia\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:30 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418094\" data-ts=\"1545222573\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ERJ\" target=\"_blank\">ERJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418094-embraerplus-2_0-after-firm-order-from-azul-for-21-jets\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Embraer +2.0% after firm order from Azul for 21 jets</a></h4><ul><li>Embraer (NYSE:<a href='https://seekingalpha.com/symbol/ERJ' title='Embraer S.A.'>ERJ</a>) <font color=\"green\">jumps 2.0%</font> in premarket trading after Brazilian airline Azul Linhas Aéreas Brasileiras <a href=\"https://seekingalpha.com/pr/17362391-embraer-azul-firm-order-additional-e195-e2-jets\" target=\"_blank\">signs a contract</a> for a firm order for previously announced 21 E195-E2 jets.</li><li>In July, Azul signed a Letter of Intent at the Farnborough Airshow for the jets, which have a contract value of $1.4B based on current list prices.</li><li>The order will be included in Embraer's Q4 2018 backlog.</li><li>Azul is the launch operator of the E195-E2 and will receive the first aircraft in 2019.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3418041-embraer-signs-pact-4-jets-value-243m\" target=\"_blank\">Embraer signs pact for up to 4 jets with value of $243M</a> (Dec. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3418094\" data-linked=\"Embraer +2.0% after firm order from Azul for 21 jets\" data-tweet=\"$ERJ - Embraer +2.0% after firm order from Azul for 21 jets https://seekingalpha.com/news/3418094-embraerplus-2_0-after-firm-order-from-azul-for-21-jets?source=tweet\" data-url=\"https://seekingalpha.com/news/3418094-embraerplus-2_0-after-firm-order-from-azul-for-21-jets\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418092\" data-ts=\"1545222533\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BBY\" target=\"_blank\">BBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418092-moffettnathanson-steps-up-to-best-buy-sidelines\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MoffettNathanson steps up to Best Buy sidelines</a></h4><ul><li>MoffettNathanson <a href=\"https://www.streetinsider.com/Analyst+Comments/MoffettNathanson+Upgrades+Best+Buy+%28BBY%29+to+Buy/14936865.html\" target=\"_blank\">upgrades</a> Best Buy (NYSE:<a href='https://seekingalpha.com/symbol/BBY' title='Best Buy Co.'>BBY</a>) from Sell to Neutral with a $52 price target.</li><li>Analyst Greg Melich says sales and margin risks are now priced into BBY.</li><li>Best Buy shares are <font color=\"green\">up 0.9%</font> premarket to $52.45.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418092\" data-linked=\"MoffettNathanson steps up to Best Buy sidelines\" data-tweet=\"$BBY - MoffettNathanson steps up to Best Buy sidelines https://seekingalpha.com/news/3418092-moffettnathanson-steps-up-to-best-buy-sidelines?source=tweet\" data-url=\"https://seekingalpha.com/news/3418092-moffettnathanson-steps-up-to-best-buy-sidelines\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418090\" data-ts=\"1545222127\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FB\" target=\"_blank\">FB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418090-another-personal-data-scandal-for-facebook-update\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Another personal data scandal for Facebook (update)</a></h4><ul><li><strong>Update:</strong> Facebook has a <a href=\"https://newsroom.fb.com/news/2018/12/facebooks-partners/\" target=\"_blank\">blog post</a> responding to the NYT report. Key quote: \"None of these partnerships or features gave companies access to information without people's permission, nor did they violate our 2012 settlement with the FTC.\"</li><li>Netflix <a href=\"https://www.reuters.com/article/us-facebook-data/facebook-says-companies-got-access-to-data-only-after-user-permission-idUSKBN1OI0QI\" target=\"_blank\">releases a statement </a>about its alleged participation: \u201cAt no time did we access people\u2019s private messages on Facebook or ask for the ability to do so.\"</li><li>Facebook (NASDAQ:<a href='https://seekingalpha.com/symbol/FB' title='Facebook'>FB</a>) gave other tech companies more access to user personal data than was previously disclosed, according to hundreds of pages of documents obtained by <a href=\"https://www.nytimes.com/2018/12/18/technology/facebook-privacy.html\" target=\"_blank\">the New York Times</a>.</li><li>Facebook user friends were visible in Microsoft Bing searches without permission, Netflix and Spotify could access Facebook messages, Amazon had user names and contact information through friends, and Yahoo could see shared friends posts, a practice Facebook said it ended, but Yahoo could still access as of the summer.</li><li>Facebook tells <a href=\"https://www.axios.com/facebook-personal-data-available-netflix-spotify-16db5cbb-0c0e-423c-ab14-6484839b66f5.html?utm_source=facebook&amp;utm_medium=social&amp;utm_campaign=organic&amp;fbclid=IwAR2PSwNnw-HSlsjg7UmCXDuu9o36vz3vLYxZog1VykmmIClOvxWJFOQUDaE\" target=\"_blank\">Axios</a>: \"Facebook\u2019s partners don't get to ignore people\u2019s privacy settings, and it\u2019s wrong to suggest that they do.\"</li><li>Facebook shares are <font color=\"red\">down 1.9%</font> premarket to $141.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418090\" data-linked=\"Another personal data scandal for Facebook (update)\" data-tweet=\"$FB - Another personal data scandal for Facebook (update) https://seekingalpha.com/news/3418090-another-personal-data-scandal-for-facebook-update?source=tweet\" data-url=\"https://seekingalpha.com/news/3418090-another-personal-data-scandal-for-facebook-update\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:22 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>122&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3418062\" data-ts=\"1545205044\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GSK\" target=\"_blank\">GSK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3418062-glaxo-pfizer-to-merge-consumer-health-units\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Glaxo, Pfizer to merge consumer health units</a></h4><ul><li>GlaxoSmithKline (NYSE:<a href='https://seekingalpha.com/symbol/GSK' title='GlaxoSmithKline'>GSK</a>) and Pfizer (NYSE:<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a>) are <a href=\"https://seekingalpha.com/pr/17362226-pfizer-glaxosmithkline-announce-joint-venture-create-premier-global-consumer-healthcare\" target=\"_blank\">combining</a> their consumer health businesses in a joint venture with sales of $12.7B, majority owned by the British company.</li><li>The transaction is expected to deliver $650M in peak cost synergies and to be slightly accretive for Pfizer.</li><li>It will also pave the way for a <a href=\"https://www.ft.com/content/3681be02-035d-11e9-9d01-cd4d49afbbe3\" target=\"_blank\">breakup</a> of GlaxoSmithKline, which intends to split into two separate businesses - one focused on consumer and one on pharma and vaccines - within three years after the close of the JV.</li><li>GSK is up <font color=\"green\">7%</font> and PFE up <font color=\"green\">1%</font> premarket, both on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3418062\" data-linked=\"Glaxo, Pfizer to merge consumer health units\" data-tweet=\"$GSK $GSK $PFE - Glaxo, Pfizer to merge consumer health units https://seekingalpha.com/news/3418062-glaxo-pfizer-to-merge-consumer-health-units?source=tweet\" data-url=\"https://seekingalpha.com/news/3418062-glaxo-pfizer-to-merge-consumer-health-units\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}